

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

BMJ Open

THE UTILITY OF KI-67 AS A PROGNOSTIC BIOMARKER IN PULMONARY NEUROENDOCRINE NEOPLASMS: A SYSTEMATIC REVIEW AND META-ANALYSIS.

Journal:	BMJ Open
Manuscript ID	bmjopen-2020-041961
Article Type:	Original research
Date Submitted by the Author:	26-Jun-2020
Complete List of Authors:	Naheed, Salma; University of Southampton Faculty of Medicine, , NIHR and CRUK Experimental Cancer Medicine Center and NIHR Biomedical Research Center Southampton; Holden, Chloe; University Hospital Southampton NHS Foundation Trust, Department of Oncology, Wessex NET group ENETS Centre of Excellence Tanno, Lulu; University of Southampton Faculty of Medicine, Cancer Sciences Unit, NIHR and CRUK Experimental Cancer Medicine Center and NIHR Biomedical Research Center Southampton Pattini, Linda; Polytechnic of Milan Department of Electronics Information and Bioengineering, Department of Electronics, Information Trust, Green, Bryan; University Hospital Southampton NHS Foundation Trust, Department of Pathology, Wessex NET group ENETS Centre of Excellence Jaynes, Eleanor; University Hospital Southampton NHS Foundation Trust, Department of Cellular Pathology, Wessex NET group ENETS Centre of Excellence Gave, Judith; University Hospital Southampton NHS Foundation Trust, Department of Cellular Pathology, Wessex NET group ENETS Centre of Excellence Cave, Judith; University Hospital Southampton NHS Foundation Trust, Department of Oncology, Wessex NET group ENETS Centre of Excellence Ottensmeier, Christian H. ; University of Southampton, Cancer Sciences Unit, NIHR and CRUK Experimental Cancer Medicine Center and NIHR Biomedical Research Center Southampton Pelosi, Giuseppe ; University of Milan, Department of Oncology and Hemato-Oncology
Keywords:	Respiratory tract tumours < THORACIC MEDICINE, Pathology < NATURAL SCIENCE DISCIPLINES, Endocrine tumours < DIABETES & ENDOCRINOLOGY

SCHOLARONE[™] Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Review only

THE UTILITY OF KI-67 AS A PROGNOSTIC BIOMARKER IN PULMONARY NEUROENDOCRINE NEOPLASMS: A SYSTEMATIC REVIEW AND META-ANALYSIS.

Salma Naheed ¹, Chloe Holden ², Lulu Tanno ¹, Pattini L³, Neil Pearce⁴, Bryan Green⁵ Eleanor Jaynes⁵, Judith Cave², Christian Ottensmeier¹, Giuseppe Pelosi⁶

¹ Cancer Sciences Unit, Faculty of Medicine, NIHR and CRUK Experimental Cancer Medicine Center and NIHR Biomedical Research Center Southampton; University of Southampton, Somers Cancer Research Building, University Hospital Southampton, Tremona Road, Southampton, UK

² Department of Oncology, Wessex NET group ENETS Centre of Excellence, University Hospital Southampton, Tremona Road, Southampton, UK

³ Department of Electronics, Information and Bioengineering, Politecnico of Milan, Milan, Italy

⁴ Department of Surgery, Wessex NET group ENETS Centre of Excellence, University Hospital Southampton, Tremona Road, Southampton, UK

⁵ Department of Cellular Pathology, Wessex NET group ENETS Centre of Excellence, University Hospital Southampton, Tremona Road, Southampton, UK

⁶ Department of Oncology and Hemato-Oncology, University of Milan, and Inter-Hospital Pathology Division, IRCCS Multimedica, Milan, Italy

Corresponding Author: Salma Naheed, s.naheed@soton.ac.uk

Word Count: 2915

ABSTRACT

Objectives: Ki-67, a marker of cellular proliferation, is associated with prognosis across a wide range of tumours including gastroenteropancreatic neuroendocrine neoplasms, lymphoma, urothelial tumours and breast carcinomas. Its omission from the classification system of pulmonary neuroendocrine neoplasms is controversial. This systematic review sought to assess whether Ki-67 is a prognostic biomarker in lung neuroendocrine neoplasms (NENs) and if feasible, proceed to a meta-analysis.

Research Design and Methods: Medline (Ovid), Embase, Scopus and the Cochrane library were searched for studies published prior to 28 February 2019 and investigating the role of Ki-67 in lung NENs. Eligible studies were those that included more than 20 patients and provided details of survival outcomes, namely hazard ratios with confidence intervals according to Ki-67 percentage. Studies not available as a full text or without an English manuscript were excluded. This study was prospectively registered with PROSPERO, number CRD42018093389.

Results: Of 11814 records identified, 7 studies met the inclusion criteria. These retrospective studies provided data for 1268 patients (693 TC, 281 AC, 94 LCNEC and 190 SCLC) and a meta-analysis was carried out to estimate a pooled effect. Random effects analyses demonstrated an association between a high Ki-67 index and poorer overall survival (HR of 2.02, 95% CI 1.16 – 3.52) and recurrence free survival (HR 1.42; 95% CI 1.01-2.00).

Conclusion: This meta-analysis provides evidence that high Ki-67 labelling indices correlate with poor clinical outcomes for patients diagnosed with pulmonary NENs. This study is subject to inherent limitations, but it does provide valuable insights regarding the use of the biomarker Ki-67, in a rare tumour.

Prospero registration: CRD42018093389

Strengths and Limitations of this study

This systematic review and meta-analysis provides a comprehensive synopsis of the literature published up to February 2020.

The protocol adheres to PRISMA guidelines, and was published in the BMJ Open ensuring transparency.

<text> Heterogeneity in methodologies, diverse cohort sizes and types and variety of endpoints considered may limit comparison across studies.

> For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

INTRODUCTION

Bronchopulmonary neuroendocrine neoplasms (NENs) encompass a rare group of malignancies which exhibit considerable diversity and behave in an extremely heterogenous manner. Derived from pulmonary enterochromaffin (peptide and amine producing) neuroendocrine cells, lung NENs are classified through a combination of morphological neuroendocrine characteristics together with additional histological parameters by the 2015 World Health Organisation (WHO) classification.(1) This classification separates pulmonary NENs into four distinct groups ranging from typical and atypical carcinoids to large cell neuroendocrine carcinomas (LCNECs) and small cell lung carcinomas (SCLCs). Typical carcinoids (TC) are well differentiated, slow growing, indolent tumours which rarely metastasize. By way of contrast, SCLCs are aggressive, poorly differentiated tumours which have frequently metastasized at the point of presentation. Clinical outcomes are also markedly different; the 10-year survival for TCs is reported to be 82-87%, whilst the prognosis for untreated metastatic small cell lung cancer is 6-12 weeks.(2–4)

Originally identified in the 1980s by Gerdes *et al*, the DNA binding nuclear protein, Ki-67, is expressed during all phases of the cell cycle barring the rest phase (G_0).(5) *MKI67*, the gene which encodes the Ki-67 protein is located on chromosome 10q26.(6) Whilst a number of studies have implicated Ki-67 in ribosomal RNA synthesis, its exact function remains elusive. Nevertheless, in the setting of malignancy, Ki-67 has become established as a robust biomarker of cellular proliferation given its characteristic property of being rapid degradation during anaphase and telophase with a short half life of 1 to 1.5 hours.

Ki-67 is most frequently evaluated immunohistochemically on paraffin sections using the MIB-1 antibody. Scoring is generally formulated by the percentage of tumour cells stained positively to the antigen (also known as the labelling index). Several methods are available to evaluate the Ki-67 labelling index (LI), including digital image analysis, eyeball estimation and manual counting. The method currently considered 'gold standard' is to evaluate the area with the most dense Ki-67 staining (i.e. histological 'hotspots') and to subsequently manually count a minimum of 500 cells, with best practice being to count 2000 cells or 2mm².(7,8) Manual counting is subject to limitations - not only can it become tedious, but it is time-consuming as counting 2000 cells can take approximately 40 minutes to complete. Utilising camera captured printed images reduces issues with inter-observer variability, although the issue of intra-tumoural heterogeneity remains as selecting which tumour area will be subjected to counting can be difficult to establish with consistency.(9) Therefore, some pathologists resort to eyeball estimations, resulting in poor reproducibility and inter-observer variability relating to the pathologists experience.(10) Digital image analysis has been heralded as a means of deriving uniformity, but it is not currently widely employed as a result of a number of obstacles including technical

issues (e.g. overcounting unwanted cells and underestimating negative cells) as well as its current lack of worldwide availability.

Across multiple tumour sites, numerous studies have determined an association between the Ki-67 LI and patient survival.(11–15) Furthermore, evidence in other solid tumours suggests that Ki-67 is also a useful predictive biomarker, predicting response to treatment such as chemotherapy; in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) it assists oncologists to determine how best to sequence treatments for patients.

Pulmonary NENs are classified on the basis of morphological characteristics including mitotic activity and the presence or absence of necrosis (2015 WHO classification). As outlined above, they are stratified into the well differentiated NETs (TC and atypical carcinoids [ACs]) and the poorly differentiated NECs (LCNECs and SCLCs). Despite each of these subtypes being endowed with behavioural heterogeneity, these tumours are not further sub-categorised according to tumour grade.(16) This places pulmonary NENs at odds with GEP-NENs where the Ki-67 index together with the mitotic rate and necrosis are important considerations when determining the grade of disease and also significantly influences how therapies are sequenced. The updated 2017 WHO classification of pancreatic NENs has progressed further, by formally recognising the heterogeneity of well differentiated NETs - a well-differentiated grade 3 NET group has been included for the first time.(17)

Whilst a number of studies have been conducted to examine the prognostic utility of Ki-67 in pulmonary NENs, its omission from the pulmonary NEN classification system remains controversial. No consensus has been established for the routine use of Ki-67 in pulmonary NENs. Nevertheless, oncologists continue to request this in the belief that this marker is predictive and/or prognostic.(18) Therefore, the primary aim of this systematic review and meta-analysis is to determine whether existing evidence supports or refutes the use of Ki-67 as a prognostic biomarker in pulmonary NENs.

METHODS

This study was prospectively registered with the International Prospective Register of Systematic Reviews (PROSPERO) website (registration number CRD42018093389) following the production of a protocol in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A copy of the PRISMA protocol is also available via the *BMJ Open*.(19)

Page 7 of 22

Search strategy and selection criteria

A systematic review was conducted evaluating the prognostic relevance of the Ki-67 LI in patients with bronchopulmonary NENs. MEDLINE Ovid, Embase, the Cochrane Library and Scopus were searched to look for relevant studies published from the inception of each database to 28 February 2019. The following search terms were employed: "Ki-67", "mib-1", "neuroendocrine tumor", "carcinoid" and "small cell lung carcinoma". References of articles included in the analysis were also screened to ensure a complete dataset was available for review.

To be eligible, studies had to provide details of prognostic outcomes (hazard ratios with confidence intervals or 5-year overall survival) in more than 20 subjects with pulmonary NENs according to Ki-67 LI. Studies which did not provide sufficient prognostic details for the pulmonary NEN cohort, studies not published in English, or not available as a full manuscript were excluded. Articles which contained only predictive outcomes were also excluded.

Two independent reviewers (SN and CH) screened the title and abstracts against the pre-defined eligibility criteria independently of each other. Where discrepancies arose, a third reviewer (GP) served as arbitrator and a collective decision was then reached. Data from the studies was extracted (SN) and reviewed (GP).

Data analysis

For each study included in the meta-analysis, the following study characteristics were extracted wherever possible: first author, year of publication, country where the study was carried out, study design, number of patients, histological subtypes, mean age, disease stage, gender distribution, length of follow-up and methodology for calculating Ki-67. Hazard ratios (HR) with 95% confidence intervals (CIs) were sought as the primary outcome measure from each study in terms of overall survival (OS), disease free survival (DFS) and recurrence free survival (RFS). Secondary outcomes for each study were five year survival rates.

The Newcastle-Ottawa Scale (as recommended by the Cochrane Non-Randomised Studies Methods Working Group) was utilised to appraise the quality of studies eligible for meta-analysis.(20) This involved appraising the selection, comparability and outcome of each study with scores ranging from 0 to 9. Scores of 0-3 indicate a low quality study, 4-5 and 6-9 are considered medium and high quality respectively. Only medium and high quality studies were considered for inclusion in the meta-analysis.

Statistical analysis

The statistical analyses were performed using the RevMan 5.3 software (Cochrane Collaboration, Copenhagen, Denmark). The generic inverse variance model was employed to pool and weight hazard

ratios. In order to assess the heterogeneity of results across studies, a pooled hazard ratio was ascertained using Higgins I² statistic. Where there was evidence of high levels of heterogeneity (i.e. I² > 50%), a random effects model was utilised. It was intended to assess the risk of bias using funnelplot visual inspections together with Begg's and Egger's test.

Role of the funding source

There was no funding source for this study. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

RESULTS

The database searches identified 11814 publications. Following the exclusion of duplicates, 8057 studies remained. 8008 articles were excluded following initial screening of titles and abstracts. The remaining 49 articles were retrieved for full text review. 42 further articles were excluded, with the main reason for exclusion being insufficient prognostic data to facilitate a meta-analysis. A flowchart of the study selection process is shown in Figure 1. Although the planned protocol had intended to also capture 5 year survival data, due to the heterogeneity of Ki-67 cut-offs utilised and data presentation via Kaplan Meier curves, it was not possible to present this in a meaningful way.

Study characteristics and quality evaluation

Seven papers, published between 2013 and 2018 including 1268 patients (693 TC, 281 AC, 94 LCNEC and 190 SCLC) fulfilled the inclusion criteria for meta-analysis.(21–27) All included studies were retrospective and observational in nature, with no prospective studies identified. The cohort sizes varied between 82 and 399 subjects. Only one study (Rindi *et al*) was inclusive of the full range of pulmonary NENs with most studies only including the well-differentiated NETs (typical and atypical carcinoids). Four of the studies included Italian cohorts, with France, Brazil, Finland and the UK each contributing a single study. The majority of studies used the MIB-1 antibody (4 of 7), although not all studies provided this information.

The majority (76.8%) of the patients had well-differentiated tumours (either in the form TC or AC) with only a minority (23.1%) having poorly differentiated NECs. 51% of the participants were female. The age range of participants varied between 15 and 83 years with one study failing to provide this information. Three studies did not report data for tumour stage. Across the remaining four studies, the majority of participants were noted to have early stage disease (54.3% of patients had stage I disease,

BMJ Open

15.5% stage II, 14.2% stage III, 13.8% stage IV, 4.2% stage X). Median length of follow-up ranged between 9.6 and 70 months. The population characteristics of studies included in the meta-analysis are summarised in Table 1.

Quality evaluation revealed that the studies included in the meta-analysis were of an overall good quality. The median Newcastle-Ottawa Scale score was seven, with three papers scoring seven and eight each and one scoring six [Table 2]. Five and three studies made hazard ratio and confidence interval data available for OS and RFS respectively.

Meta-analysis of overall survival

In the meta-analysis of overall survival, five studies were included (Cusumano *et al* published a death HR, whilst Vesterinen *et al* offered a HR for disease specific mortality – both were deemed to be surrogate markers of OS).(21,22) Hazard ratios derived from univariate analyses were considered for meta-analysis over their multivariate counterparts in an effort to limit the heterogeneity resulting from how hazard ratios are derivation. The pooled HR for Ki-67 was 2.02 (95% CI 1.16 – 3.52) with a p-value of 0.01 [Figure 2]. The heterogeneity was high: $I^2 = 69\%$. This necessitated use of a random effects model.

Meta-analysis of recurrence free survival

In the meta-analysis of recurrence free survival (RFS), three studies were available (in one recurrence HR was available whilst a second study provided a time to progression HR – both were considered to be surrogate markers of RFS). The pooled HR was 1.42 (95% CI 1.01-2.00; p 0.04) [Figure 3]. Once again, the heterogeneity was high ($I^2 = 89\%$) and therefore a random effects model was appropriate.

Risk of bias

Despite the intention to assess the risk of bias using funnel-plot visual inspections, Begg's and Egger's test, this was not feasible due to the low number of studies included in the meta-analysis.

DISCUSSION

Prognostic biomarkers and tools play an important role in oncological management and decision making processes. In pulmonary NENs the dearth of prognostic biomarkers is notable and therefore oncologists often request Ki-67 indices in order to assist in therapeutic decisions despite the fact this has not been

formally adopted. The primary aim of this study was to evaluate whether existing Ki-67 LI is associated with prognosis in pulmonary NENs as has been demonstrated in numerous other tumour types (e.g. urothelial carcinomas, breast cancer, lymphoma and lung cancer).

This meta-analysis provides tentative evidence demonstrating that high Ki-67 indices are associated with a 40% greater risk of recurrence amongst patients diagnosed with pulmonary NENs. This risk appears to be further exaggerated when considering overall survival where patients with a high Ki-67 have double the risk of death in comparison with patients with a lower Ki-67 LI. The strength of the association between Ki-67 LI and prognosis was only evaluated in studies that calculated hazard ratios using univariate analyses. As a result, no attempt has been made to account for confounding factors (such as stage, grade, and mitotic index).

One of the major pitfalls of including Ki-67 in the classification of pulmonary NENs has in establishing the most appropriate thresholds or cut-offs that should be utilised when grading tumours. In the main, Ki-67 has not been used as a linear biomarker within the whole pulmonary NEN cohort, instead focusing on its utility within each categorical histological subtype. Whilst categorising NENs by grade is helpful in establishing management plans, it is likely that proliferative markers (such as Ki-67 and mitotic index) are continuous rather than categorical variables. Therefore, there may not be a single or absolute optimal cut off value to categorise tumours into distinct entities and a pragmatic approach is likely to be needed. In order to facilitate clinical clarity, it would be preferable to use the same thresholds as are utilised in GEP-NETs and any future studies should attempt to clarify this further. However, it is unclear whether attempting to implement a similar grading system in pulmonary NENs as GEP NENs does a disservice to the fundamental biological diversity between the two different tumour sites.

As with all studies, this meta-analysis is also subject to inherent limitations. None of the studies included in the meta-analyses were prospective in design; retrospective analyses are prone to error through issues with selection bias and reporting. Secondly, studies with a variety of endpoints (e.g. RFS analyses included studies where the endpoint was DFS and time to progression analyses etc.), diverse cohort sizes, differences in the dilution of the primary antibody as well as variable Ki-67 cut-offs have all been amalgamated. Whilst some degree of heterogeneity is always to be expected, it diminishes the validity of the combined data-set and subsequent results. This is reflected in the I² statistics noted across both meta-analyses.

This study also preferentially utilised univariate analyses. Whilst multivariate analyses can be significantly distorted by differing in their approach to modelling or prognostic factors, univariate analyses fail to account for confounding variables. Furthermore, given the small number of studies identified as suitable for inclusion in this meta-analysis, it is clear that future international multi-centre

efforts are needed to develop studies which are prospective with large cohorts to clarify whether Ki-67 labelling index is truly a prognostic biomarker in the setting of bronchopulmonary neuroendocrine neoplasms.

CONCLUSIONS

Although it is difficult to draw definitive conclusions, this meta-analysis of over 1250 patients with pulmonary NENs indicates that a high Ki-67 LI correlates with an adverse prognosis. Whilst these findings are subject to a number of limitations, they provide a valuable insight into a rare tumour and should be considered when producing new guidelines regarding the use of Ki-67 in pulmonary NENs.

Conflict of interest statement: The authors have declared no competing interests.

Acknowledgments: This research is an academic spontaneous study, which received no specific grant from any funding agency, commercial or not-for profit sectors.

SN's postgraduate studies are funded by PLANETS Cancer Charity, a not for profit organisation which had no role in developing this protocol or performing the meta-analysis.

Patient and public involvement: Patients and the public were not involved in the development of this systematic review or meta-analysis.

REFERENCES

- 1. Travis WD Burke AP, Marx A, Nicolson AG. BE. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. . Int Agency Res Cancer. 2015;
- 2. Asamura H, Kameya T, Matsuno Y, Noguchi M, Tada H, Ishikawa Y, et al. Neuroendocrine neoplasms of the lung: A prognostic spectrum. J Clin Oncol. 2006;24(1):70–6.
- Ducrocq X, Thomas P, Massard G, Barsotti P, Giudicelli R, Fuentes P, et al. Operative risk and prognostic factors of typical bronchial carcinoid tumors. Ann Thorac Surg [Internet]. 1998/05/22. 1998;65(5):1410–4. Available from: https://www.ncbi.nlm.nih.gov/pubmed/9594876
- Soga J, Yakuwa Y. Bronchopulmonary carcinoids: An analysis of 1,875 reported cases with special reference to a comparison between typical carcinoids and atypical varieties. Ann Thorac Cardiovasc Surg [Internet]. 1999/10/06. 1999;5(4):211–9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/10508944
- Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J cancer [Internet]. 1983 Jan 15 [cited 2019 Feb 13];31(1):13–20. Available from: http://www.ncbi.nlm.nih.gov/pubmed/6339421
- Menon SS, Guruvayoorappan C, Sakthivel KM, Rasmi RR. Ki-67 protein as a tumour proliferation marker. Clin Chim Acta [Internet]. 2019 Apr 14 [cited 2019 Feb 14];491:39–45. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30653951
- Fabbri A, Cossa M, Sonzogni A, Papotti M, Righi L, Gatti G, et al. Ki-67 labeling index of neuroendocrine tumors of the lung has a high level of correspondence between biopsy samples and surgical specimens when strict counting guidelines are applied. Virchows Arch [Internet]. 2017 Feb 4 [cited 2019 Mar 26];470(2):153–64. Available from: http://link.springer.com/10.1007/s00428-016-2062-2
- Pelosi G, Rindi G, Travis WD, Papotti M. Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice. J Thorac Oncol [Internet]. 2014 Mar [cited 2019 Mar 26];9(3):273–84. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1556086415302094
- Reid MD, Bagci P, Ohike N, Saka B, Erbarut Seven I, Dursun N, et al. Calculation of the Ki67 index in pancreatic neuroendocrine tumors: a comparative analysis of four counting methodologies. Mod Pathol [Internet]. 2015 May 21 [cited 2019 Mar 26];28(5):686–94. Available from: http://www.nature.com/articles/modpathol2014156
- Klimstra DS, Modlin IR, Adsay NV, Chetty R, Deshpande V, Gönen M, et al. Pathology Reporting of Neuroendocrine Tumors: Application of the Delphic Consensus Process to the

BMJ Open

2	
3 4 5	Development of a Minimum Pathology Data Set. Am J Surg Pathol [Internet]. 2010 Mar [cited 2019 Feb 13];34(3):300–13. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20118772
6 7 11. 8 9 10 11 12	de Azambuja E, Cardoso F, de Castro G, Colozza M, Mano MS, Durbecq V, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients. Br J Cancer [Internet]. 2007 May 24 [cited 2019 Feb 13];96(10):1504–13. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17453008
13 12. 14 15 16 17 18	Khor L-Y, Bae K, Paulus R, Al-Saleem T, Hammond ME, Grignon DJ, et al. MDM2 and Ki-67 Predict for Distant Metastasis and Mortality in Men Treated With Radiotherapy and Androgen Deprivation for Prostate Cancer: RTOG 92-02. J Clin Oncol [Internet]. 2009 Jul 1 [cited 2019 Feb 14];27(19):3177–84. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19470936
19 13. 20 13. 21 22 23 24 25 25	Jann H, Roll S, Couvelard A, Hentic O, Pavel M, Müller-Nordhorn J, et al. Neuroendocrine tumors of midgut and hindgut origin: Tumor-node-metastasis classification determines clinical outcome. Cancer [Internet]. 2011 Aug 1 [cited 2019 Feb 14];117(15):3332–41. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21246527
25 26 14. 27 28 29 30 31	Klöppel G, La Rosa S. Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms. Virchows Arch [Internet]. 2018 Mar 13 [cited 2019 Feb 14];472(3):341–9. Available from: http://link.springer.com/10.1007/s00428-017-2258-0
32 15. 33 34 35 36	Taylor SR, Ewings SM, Jaynes E, Tilley C, Ellis SG, Armstrong T, et al. The assessment of Ki- 67 as a prognostic marker in neuroendocrine tumours: A systematic review and meta-analysis. J Clin Pathol. 2016;69(7):612–8.
37 16. 38 39 40 41	Pelosi G, Bianchi F, Hofman P, Pattini L, Ströbel P, Calabrese F. Recent advances in the molecular landscape of lung neuroendocrine tumors. Expert Rev Mol Diagn [Internet]. 2019;19(4):1–17. Available from: https://doi.org/10.1080/14737159.2019.1595593
42 17. 43 44 45 46 47	Inzani F, Petrone G, Rindi G. The New World Health Organization Classification for Pancreatic Neuroendocrine Neoplasia. Endocrinol Metab Clin North Am [Internet]. 2018 Sep [cited 2019 Jun 26];47(3):463–70. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0889852918305206
48 49 18. 50 51 52	Marchevsky AM, Hendifar A, Walts AE. The use of Ki-67 labeling index to grade pulmonary well-differentiated neuroendocrine neoplasms: current best evidence. Mod Pathol [Internet]. 2018;31(10):1523–31. Available from: http://dx.doi.org/10.1038/s41379-018-0076-9
53 54 19. 55 56 57	Review AS, Naheed S, Holden C, Tanno L, Jaynes E, Cave J. BMJ Open THE UTILITY OF KI-67 AS A PROGNOSTIC BIOMARKER IN PULMONARY NEUROENDOCRINE TUMOURS : PROTOCOL FOR Fo r p ee r r ev iew on Fo r p r r. 2019.
58 59 20. 60	Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol [Internet]. 2010 Sep 22 [cited 2019


Jul 5];25(9):603–5. Available from: http://link.springer.com/10.1007/s10654-010-9491-z 21. Cusumano G, Fournel L, Strano S, Damotte D, Charpentier MC, Galia A, et al. Surgical Resection for Pulmonary Carcinoid: Long-Term Results of Multicentric Study-The Importance of Pathological N Status, More Than We Thought. Lung. 195(6):789-98. 22. Vesterinen T, Mononen S, Salmenkivi K, Mustonen H, Ilonen I, Knuuttila A, et al. Clinicopathological indicators of survival among patients with pulmonary carcinoid tumor. Acta Oncol (Madr). :1-8. 23. Marchio C, Gatti G, Massa F, Bertero L, Filosso P, Pelosi G, et al. Distinctive pathological and clinical features of lung carcinoids with high proliferation index. Virchows Arch [Internet]. 471(6):713-20. Available from: https://iris.unito.it/retrieve/handle/2318/1642799/345259/Marchio C et al-VA 2017.pdf 24. Filosso PL, Oliaro A, Ruffini E, Bora G, Lyberis P, Asioli S, et al. Outcome and prognostic factors in bronchial carcinoids: A single-center experience. J Thorac Oncol [Internet]. 2013;8(10):1282-8. Available from: https://ac.els-cdn.com/S1556086415330203/1-s2.0-S1556086415330203-main.pdf? tid=586d5bf8-d0c1-46d5-94be-1c88da11e7b6&acdnat=1532082916 8a4429fa7e82a8e258d9f2cd8ce9c2bb 25. Clay V, Papaxoinis G, Sanderson B, Valle JW, Howell M, Lamarca A, et al. Evaluation of diagnostic and prognostic significance of Ki-67 index in pulmonary carcinoid tumours. Clin Transl Oncol [Internet]. 2016/11/17. 2017;19(5):579-86. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27848218 26. Rindi G, Klersy C, Inzani F. A three tier grading system based on Ki-67 index, mitotic count and necrosis with cut-offs specifically generated for lung neuroendocrine tumors is prognostically effective and accurate. Neuroendocrinology. 2014;99:251. 27. de MRJF, de Medeiros RSS, Braghiroli MI, Galvao B, Neto JEB, Munhoz RR, et al. Expression of ERCC1, Bcl-2, Lin28a, and Ki-67 as biomarkers of response to first-line platinum-based chemotherapy in patients with high-grade extrapulmonary neuroendocrine carcinomas or small cell lung cancer. Ecancermedicalscience. 11:767.

For peer teriew only

							BMJ Open			6/bmjopen-:			Page 16 of 22
1 2 3 4	Author (Year)	Trial Design (study centres)	Number of Subjects	Histological subtypes	Age Range	Gender M:F	Stage	Antibody	Methodology for calculating Ki-67	22 Median length of follow-up (months) 9 61	Ki-67 cut-off thresholds (%)	Outcome measure	Hazard Ratio (95% Cl) from univariate analyses
5 6 7 8	Cusumano et al (2017)	Retrospective multicentre study (France, Italy)	195	TC (159); AC (36)	52.94 (TC); 60.16 (AC) [mean values]	89:106	I = 163; II = 16; III = 16; IV = 0	NR	NR	75 (nBean) ω March	NR	OS (Death HR) DFS	1.07 (0.97- 1.17) 0.97 (1.01–1.2)
9 10 11 12	Rego et al (2017)	Retrospective, multicentre study (Brazil)	82	SCLC (82)	35-81 (mean 59)	48:34	I = 0; II = 0; III = 6; IV = 76	MIB-1 (1:1000)	Hotspot method; otherwise not specified	10.3 <mark>20</mark> 2022 2.	55	OS	1.15 (0.70- 1.89)
13 14 15 16	Marchio et al (2017)	Retrospective multicentre study (Italy)	239	TC (171); AC (68)	NR	100:139	NR	NR	Manual counting of >1000 cells	Downloaded from	4	OS TTP	4.31 (1.624- 11.45) 3.994 (1.58-10)
17 18 19 20 21 22	Filosso et al (2013)	Retrospective, single centre study (Italy)	126 [NB 110 included in Ki- 67 analysis]	TC (83); AC (43). [In Ki-67 analysis TC (79); AC (31)]	15-82 (mean 60)	52:74	I = 90; II = 18; III = 16; IV = 2; X = 1	anti–Ki-67 antibody (DAKO) not further specified	NR	from http://bmjopen.bm 60	6	OS	2.08 (1.02- 4.27)
23 24 25 26 27	Rindi et al (2014)	Retrospective, multicentre study (Italy)	399	TC (113); AC (84); LCNEC (94); SCLC (108)	63.26 (median)	245:154	I = 183; II = 90; III = 76; IV = 17; X = 33	MIB-1 antibody	Computer assisted manual count method 500- 2000 cells	n. 70.7com/ on April	<4 vs 4-20	OS	1.26 (0.84- 1.89)
28 29 30 31 32 33	Clay et al (2017)	Retrospective, single centre study (UK)	94 [NB survival analysis performed on 84]	TC (75); AC (19) [NB survival analysis performed 67 TC, 17 AC patients]	21-83 (median 60.5)	39:55	NR	MIB-1 antibody (1:50)	Manual count method 500- 2000 cells in hot spot	il 19, 2024 by gues	NR	RFS	1.47 (1.25- 1.74)
34 35 36 37	Vesterinen et al (2018)	Retrospective, single centre study (Finland)	133 (129 included in Ki- 67 analysis)	TC (100); AC (33)		47:86	NR	MIB-1 antibody (1:100)	Manual and automated counting of 2000 cells	9.6 9.6	2.5	Disease specific mortality	10.51 (2.12- 52.13)
38 - 39 40 41 42				es included in RFS = recurrer		-	ase free surviv 15	val, TTP = time	to progressic	by cop			
42 43 44 45				F	or peer review	only - http://bi		m/site/about/g	guidelines.xhtn	nl			

2				BMJ	Open		5/bmjopen-2020-0සු10 Adeg		
Author (Year)	Representativeness of cohort	Adequate definition of cases	Assessment of exposure	Outcome of interest not present at start of study		Assessment of Outcome (death or recurrence)	for outcome (>2 years)	Adequacy of follow-up of cases (<20% or reported)	Total Qualit Score
	(1 point)	(1 point)	(1 point)	(1 point)	(2 points)	(1 point)	ω (1pgoint)	(1 point)	
Cusumano et al (2017)	${\searrow}$	Δ		-	$\mathcal{A}\mathcal{A}$		are(X202	Δ	8
Rego et al (2017)	\mathbf{x}	$\overrightarrow{\mathbf{x}}$	$\overrightarrow{\mathbf{x}}$	-	\mathbf{x}	$\overrightarrow{\mathbf{A}}$	2Do	$\overrightarrow{\lambda}$	6
Marchio et al (2017)	${\checkmark}$	\$	\$	-	$\overrightarrow{\mathbf{x}}$	\mathbf{x}	wnloade	Δ	7
Filosso et al (2013)	${\searrow}$	$\overrightarrow{\mathbf{A}}$	\$		$\mathcal{A}\mathcal{A}$			\checkmark	8
Rindi et al (2014)	$\overset{\mathbf{A}}{\bowtie}$	$\overrightarrow{\mathbf{A}}$		02	$\overrightarrow{\mathbf{x}}$	$\overrightarrow{\mathbf{A}}$	The second se	$\overrightarrow{\lambda}$	8
Clay et al (2017)	${\checkmark}$	Δ		- 16	*	\mathbf{k}	Dirakaper	Δ	7
Vesterinen et al (2018)	$\overset{\mathbf{A}}{\Join}$		$\overrightarrow{\mathbf{A}}$	-	**	A	ı.bmj.com	\checkmark	7
Table 2:	Quality assessmen	t of included s	studies utilising	g the (modified)	Newcastle-Otta	wa Scale.	re)2022. Downloaded from http://bm/gpen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.		
							ÝT.		

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml



1							
2							
3							
4 5							
6							
7							
8							
9 10							
11							
12							
13							
14 15							
16							
17							
18 19							
20							
21							
22							
23 24							
25				Hazard Ratio		Hazard Ratio	
26 -	Study or Subgroup Filosso 2013	log[Hazard Ratio] SE 1 0.7324 0.3636	Total Total Weight 0 0 21.2%	IV, Random, 95% CI Year 2.08 [1.02, 4.24] 2013		Random, 95% Cl	_
27 28	Rindi 2014	0.2311 0.2069	0 0 27.8%	1.26 [0.84, 1.89] 2014			
20	Rego 2017	0.1398 0.2533	0 0 25.9%	1.15 [0.70, 1.89] 2017		- -	
30	Marchio 2017 Vesterinen 2018	1.4609 0.498 2.3523 0.8168	0 0 16.3% 0 0 8.8%	4.31 [1.62, 11.44] 2017 10.51 [2.12, 52.10] 2018			
31			0 0 100 09/	2 02 [4 46 2 52]			
32	Total (95% CI) Heterogeneity: Tau ² = 0.	25; Chi² = 12.75, df = 4 (P = 0	0 0 100.0% 0.01); I ² = 69%	2.02 [1.16, 3.52]		•	
		25; Chi² = 12.75, df = 4 (P = 0 = 2.47 (P = 0.01)		2.02 [1.16, 3.52]	⊢ <u> </u>	1 10 100	
32 33 34 35	Heterogeneity: Tau ² = 0.				⊢ 0.01 0.1		
32 33 34 35 36	Heterogeneity: Tau ² = 0.			2.02 [1.16, 3.52]	H <u>H</u> 0.01 0.1	1 10 100	
32 33 34 35	Heterogeneity: Tau ² = 0. Test for overall effect: Z Figure 2: Forest	= 2.47 (P = 0.01) plot of studies evalua	0.01); I² = 69%				
32 33 34 35 36 37 38 39	Heterogeneity: Tau ² = 0. Test for overall effect: Z Figure 2: Forest	= 2.47 (P = 0.01)	0.01); I² = 69%	ion between Ki-67 e	xpression and		
32 33 34 35 36 37 38 39 40	Heterogeneity: Tau ² = 0. Test for overall effect: Z Figure 2: Forest	= 2.47 (P = 0.01) plot of studies evalua	0.01); I² = 69%	ion between Ki-67 e	xpression and		
32 33 34 35 36 37 38 39 40 41	Heterogeneity: Tau ² = 0. Test for overall effect: Z Figure 2: Forest	= 2.47 (P = 0.01) plot of studies evalua	0.01); I² = 69%	ion between Ki-67 e	xpression and		
32 33 34 35 36 37 38 39 40 41 42 43	Heterogeneity: Tau ² = 0. Test for overall effect: Z Figure 2: Forest	= 2.47 (P = 0.01) plot of studies evalua	0.01); I² = 69%	ion between Ki-67 e			
32 33 34 35 36 37 38 39 40 41 42 43 44	Heterogeneity: Tau ² = 0. Test for overall effect: Z Figure 2: Forest	= 2.47 (P = 0.01) plot of studies evalua	0.01); I² = 69%	ion between Ki-67 e	xpression and		
32 33 34 35 36 37 38 39 40 41 42 43 44 45	Heterogeneity: Tau ² = 0. Test for overall effect: Z Figure 2: Forest	= 2.47 (P = 0.01) plot of studies evalua	0.01); I² = 69%	ion between Ki-67 e	xpression and		
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47	Heterogeneity: Tau ² = 0. Test for overall effect: Z Figure 2: Forest	= 2.47 (P = 0.01) plot of studies evalua	0.01); I² = 69%	ion between Ki-67 e	xpression and		
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48	Heterogeneity: Tau ² = 0. Test for overall effect: Z Figure 2: Forest	= 2.47 (P = 0.01) plot of studies evalua	0.01); I² = 69%	ion between Ki-67 e	xpression and		
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49	Heterogeneity: Tau ² = 0. Test for overall effect: Z Figure 2: Forest	= 2.47 (P = 0.01) plot of studies evalua	0.01); I² = 69%	ion between Ki-67 e	xpression and		
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48	Heterogeneity: Tau ² = 0. Test for overall effect: Z Figure 2: Forest	= 2.47 (P = 0.01) plot of studies evalua	0.01); I² = 69%	ion between Ki-67 e	xpression and		
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52	Heterogeneity: Tau ² = 0. Test for overall effect: Z Figure 2: Forest	= 2.47 (P = 0.01) plot of studies evalua	0.01); I² = 69%	ion between Ki-67 e	xpression and		
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53	Heterogeneity: Tau ² = 0. Test for overall effect: Z Figure 2: Forest	= 2.47 (P = 0.01) plot of studies evalua	0.01); I² = 69%	ion between Ki-67 e	xpression and		
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52	Heterogeneity: Tau ² = 0. Test for overall effect: Z Figure 2: Forest	= 2.47 (P = 0.01) plot of studies evalua	0.01); I² = 69%	ion between Ki-67 e	xpression and		
$\begin{array}{c} 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 39\\ 40\\ 41\\ 42\\ 43\\ 44\\ 45\\ 46\\ 47\\ 48\\ 49\\ 50\\ 51\\ 52\\ 53\\ 54\\ 55\\ 56\end{array}$	Heterogeneity: Tau ² = 0. Test for overall effect: Z Figure 2: Forest	= 2.47 (P = 0.01) plot of studies evalua	0.01); I² = 69%	ion between Ki-67 e	xpression and		
$\begin{array}{c} 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 39\\ 40\\ 41\\ 42\\ 43\\ 44\\ 45\\ 46\\ 47\\ 48\\ 49\\ 50\\ 51\\ 52\\ 53\\ 54\\ 55\\ 56\\ 57\end{array}$	Heterogeneity: Tau ² = 0. Test for overall effect: Z Figure 2: Forest	= 2.47 (P = 0.01) plot of studies evalua	0.01); I² = 69%	ion between Ki-67 e	xpression and		
$\begin{array}{c} 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 39\\ 40\\ 41\\ 42\\ 43\\ 44\\ 45\\ 46\\ 47\\ 48\\ 49\\ 50\\ 51\\ 52\\ 53\\ 54\\ 55\\ 56\end{array}$	Heterogeneity: Tau ² = 0. Test for overall effect: Z Figure 2: Forest	= 2.47 (P = 0.01) plot of studies evalua roendocrine neoplasn	0.01); I ² = 69% nting the associat ns.	ion between Ki-67 e	xpression and	overall survival in	

1												
1												
2												
3												
4												
5												
6												
7												
8												
9												
10												
11												
12												
13												
14												
15												
16												
17												
18												
19												
20												
21												
22												
23												
24												
25												
26	Chudu an Culamana	leaflineed Detial	85	Total	Tadal	Malada	Hazard Ratio			azard Ratio		
27 -	Study or Subgroup	log[Hazard Ratio]				Weight			IV, R	andom, 95%		1
28	Cusamano 2017 Marchio 2017	0.0862 1.3848		0 0	0 0	46.5% 10.5%	1.09 [1.01, 1.18] 2017 3.99 [1.58, 10.10] 2017				<u> </u>	
29	Clay 2017	0.3853		0	0		1.47 [1.25, 1.73] 2017					
	014 2017	0.0000	0.0021			40.070	1.47 [1.20, 1.70] 2017					
30												
30 31	Total (95% CI)			0	0	100.0%	1.42 [1.01, 2.00]			•		
	Total (95% CI) Heterogeneity: Tau ² =						1.42 [1.01, 2.00]			•	10	100
31		0.06; Chi² = 17.59, df					1.42 [1.01, 2.00])	0.1	◆	10	100
31 32 33	Heterogeneity: Tau ² =	0.06; Chi² = 17.59, df					1.42 [1.01, 2.00]	0.01	0.1	•		100
31 32 33 34	Heterogeneity: Tau ² =	0.06; Chi² = 17.59, df					1.42 [1.01, 2.00]	0.01	0.1	1	10	100
31 32 33 34 35	Heterogeneity: Tau ² =	0.06; Chi² = 17.59, df					1.42 [1.01, 2.00]	0.01	0.1	1	10	100
31 32 33 34 35 36	Heterogeneity: Tau ² =	0.06; Chi² = 17.59, df					1.42 [1.01, 2.00]	0.01	0.1	1	10	100
31 32 33 34 35 36 37	Heterogeneity: Tau ² = Test for overall effect:	0.06; Chi² = 17.59, df Z = 2.02 (P = 0.04)	f = 2 (P =	0.0002); ² = {	89%				• 1		100
31 32 33 34 35 36 37 38	Heterogeneity: Tau ² = Test for overall effect: Figure 3: Forest	0.06; Chi² = 17.59, df Z = 2.02 (P = 0.04) plot of studies e	f = 2 (P = valuati	0.0002 ng the); ² = {	89%	1.42 [1.01, 2.00] between Ki-67 expres			• 1 e free sur		100
31 32 33 34 35 36 37 38 39	Heterogeneity: Tau ² = Test for overall effect:	0.06; Chi² = 17.59, df Z = 2.02 (P = 0.04) plot of studies e	f = 2 (P = valuati	0.0002 ng the); ² = {	89%				• 1 e free sur		100
31 32 33 34 35 36 37 38 39 40	Heterogeneity: Tau ² = Test for overall effect: Figure 3: Forest	0.06; Chi² = 17.59, df Z = 2.02 (P = 0.04) plot of studies e	f = 2 (P = valuati	0.0002 ng the); ² = {	89%				• 1 e free sur		100
31 32 33 34 35 36 37 38 39 40 41	Heterogeneity: Tau ² = Test for overall effect: Figure 3: Forest	0.06; Chi² = 17.59, df Z = 2.02 (P = 0.04) plot of studies e	f = 2 (P = valuati	0.0002 ng the); ² = {	89%				e free sur		100
31 32 33 34 35 36 37 38 39 40 41 42	Heterogeneity: Tau ² = Test for overall effect: Figure 3: Forest	0.06; Chi² = 17.59, df Z = 2.02 (P = 0.04) plot of studies e	f = 2 (P = valuati	0.0002 ng the); ² = {	89%				e free sur		100
31 32 33 34 35 36 37 38 39 40 41 42 43	Heterogeneity: Tau ² = Test for overall effect: Figure 3: Forest	0.06; Chi² = 17.59, df Z = 2.02 (P = 0.04) plot of studies e	f = 2 (P = valuati	0.0002 ng the); ² = {	89%				e free sur		100
31 32 33 34 35 36 37 38 39 40 41 42 43 44	Heterogeneity: Tau ² = Test for overall effect: Figure 3: Forest	0.06; Chi² = 17.59, df Z = 2.02 (P = 0.04) plot of studies e	f = 2 (P = valuati	0.0002 ng the); ² = {	89%				e free sur		100
31 32 33 34 35 36 37 38 39 40 41 42 43 44 45	Heterogeneity: Tau ² = Test for overall effect: Figure 3: Forest	0.06; Chi² = 17.59, df Z = 2.02 (P = 0.04) plot of studies e	f = 2 (P = valuati	0.0002 ng the); ² = {	89%				e free sur		100
 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 	Heterogeneity: Tau ² = Test for overall effect: Figure 3: Forest	0.06; Chi² = 17.59, df Z = 2.02 (P = 0.04) plot of studies e	f = 2 (P = valuati	0.0002 ng the); ² = {	89%				e free sur		100
 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 	Heterogeneity: Tau ² = Test for overall effect: Figure 3: Forest	0.06; Chi² = 17.59, df Z = 2.02 (P = 0.04) plot of studies e	f = 2 (P = valuati	0.0002 ng the); ² = {	89%				e free sur		100
 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 	Heterogeneity: Tau ² = Test for overall effect: Figure 3: Forest	0.06; Chi² = 17.59, df Z = 2.02 (P = 0.04) plot of studies e	f = 2 (P = valuati	0.0002 ng the); ² = {	89%				e free sur		100
 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 	Heterogeneity: Tau ² = Test for overall effect: Figure 3: Forest	0.06; Chi² = 17.59, df Z = 2.02 (P = 0.04) plot of studies e	f = 2 (P = valuati	0.0002 ng the); ² = {	89%				e free sur		100
 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 	Heterogeneity: Tau ² = Test for overall effect: Figure 3: Forest	0.06; Chi² = 17.59, df Z = 2.02 (P = 0.04) plot of studies e	f = 2 (P = valuati	0.0002 ng the); ² = {	89%				e free sur		100
 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 	Heterogeneity: Tau ² = Test for overall effect: Figure 3: Forest	0.06; Chi² = 17.59, df Z = 2.02 (P = 0.04) plot of studies e	f = 2 (P = valuati	0.0002 ng the); ² = {	89%				e free sur		100
 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 	Heterogeneity: Tau ² = Test for overall effect: Figure 3: Forest	0.06; Chi² = 17.59, df Z = 2.02 (P = 0.04) plot of studies e	f = 2 (P = valuati	0.0002 ng the); ² = {	89%				e free sur		100
 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 	Heterogeneity: Tau ² = Test for overall effect: Figure 3: Forest	0.06; Chi² = 17.59, df Z = 2.02 (P = 0.04) plot of studies e	f = 2 (P = valuati	0.0002 ng the); ² = {	89%				e free sur		100
 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 	Heterogeneity: Tau ² = Test for overall effect: Figure 3: Forest	0.06; Chi² = 17.59, df Z = 2.02 (P = 0.04) plot of studies e	f = 2 (P = valuati	0.0002 ng the); ² = {	89%				e free sur		100
 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 	Heterogeneity: Tau ² = Test for overall effect: Figure 3: Forest	0.06; Chi² = 17.59, df Z = 2.02 (P = 0.04) plot of studies e	f = 2 (P = valuati	0.0002 ng the); ² = {	89%				e free sur		100
$\begin{array}{c} 31\\ 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 39\\ 40\\ 41\\ 42\\ 43\\ 44\\ 45\\ 46\\ 47\\ 48\\ 49\\ 50\\ 51\\ 52\\ 53\\ 54\\ 55\\ 56\end{array}$	Heterogeneity: Tau ² = Test for overall effect: Figure 3: Forest	0.06; Chi² = 17.59, df Z = 2.02 (P = 0.04) plot of studies e	f = 2 (P = valuati	0.0002 ng the); ² = {	89%				e free sur		100
$\begin{array}{c} 31\\ 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 39\\ 40\\ 41\\ 42\\ 43\\ 44\\ 45\\ 46\\ 47\\ 48\\ 49\\ 50\\ 51\\ 52\\ 53\\ 54\\ 55\\ 56\\ 57\\ \end{array}$	Heterogeneity: Tau ² = Test for overall effect: Figure 3: Forest	0.06; Chi² = 17.59, df Z = 2.02 (P = 0.04) plot of studies e	f = 2 (P = valuati	0.0002 ng the); ² = {	89%				e free sur		100
$\begin{array}{c} 31\\ 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 39\\ 40\\ 41\\ 42\\ 43\\ 44\\ 45\\ 46\\ 47\\ 48\\ 49\\ 50\\ 51\\ 52\\ 53\\ 54\\ 55\\ 56\\ 57\\ 58\end{array}$	Heterogeneity: Tau ² = Test for overall effect: Figure 3: Forest	0.06; Chi² = 17.59, df Z = 2.02 (P = 0.04) plot of studies e	f = 2 (P = valuati	0.0002 ng the); ² = {	89%				e free sur		100
$\begin{array}{c} 31\\ 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 39\\ 40\\ 41\\ 42\\ 43\\ 445\\ 46\\ 47\\ 48\\ 49\\ 50\\ 51\\ 52\\ 53\\ 54\\ 55\\ 56\\ 57\\ 58\\ 59\end{array}$	Heterogeneity: Tau ² = Test for overall effect: Figure 3: Forest	0.06; Chi ² = 17.59, df Z = 2.02 (P = 0.04) plot of studies e pendocrine neo;	f = 2 (P = valuati plasms	0.0002 ng the); I ² = {	B9%	between Ki-67 expres	ssion ar	nd diseas	e free sur		100
$\begin{array}{c} 31\\ 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 39\\ 40\\ 41\\ 42\\ 43\\ 44\\ 45\\ 46\\ 47\\ 48\\ 49\\ 50\\ 51\\ 52\\ 53\\ 54\\ 55\\ 56\\ 57\\ 58\end{array}$	Heterogeneity: Tau ² = Test for overall effect: Figure 3: Forest	0.06; Chi ² = 17.59, df Z = 2.02 (P = 0.04) plot of studies e pendocrine neo;	f = 2 (P = valuati plasms	0.0002 ng the); I ² = {	B9%		ssion ar	nd diseas	e free sur		100



PRISMA 2009 Checklist

			BMJ Open 1386	Page 22 of 22
1 2	PRISMA 20	09	BMJ Open 36/ Daj Open Checklist	
3 4 5	Section/topic	#	Checklist item	Reported on page #
6 7	TITLE		9	
8	Title	1	Identify the report as a systematic review, meta-analysis, or both. $\overset{\omega}{\leq}$	1
9 1	ABSTRACT			
1 1 1	Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data source study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
1 1	INTRODUCTION			
1	Rationale	3	Describe the rationale for the review in the context of what is already known.	3-4
1 1 1	Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, in grventions, comparisons, outcomes, and study design (PICOS).	4
2	METHODS			
2	Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and if available, provide registration information including registration number.	4
2 2	Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5
2	Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
2		8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	5
3	Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	5
3	Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	5
3		11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	5
3 3 4	Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	5-6
4	Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	5-6
4 4 4	Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including near assures of consistency (e.g., I ²) for each meta-analysis.	5-6
4 4 4	6		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml Page 1 of 2	·



45 46 47

PRISMA 2009 Checklist

Page 23 of 22		BMJ Open 33	
PRISMA 2	2009	Checklist 202	
⁴ 5 Section/topic	#	Checklist item	Reported on page #
 Risk of bias across studies 	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	5-6
9 Additional analyses10	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	5-6
		0222	
13 Study selection 14	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	6
15 Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	6-7
18 Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	7
19 Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summare data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	6-7
22 Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of sonsistency.	7
²³ Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	7
25 Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	7
26 27 DISCUSSION		<u> </u>	
28 Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	7-8
30 31 Limitations 32	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	7-8
33 Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implication for future research.	9
35 FUNDING			
³⁶ 37 38	27	Describe sources of funding for the systematic review and other support (e.g., supply of data; role of funders for the systematic review.	6
41 doi:10.1371/journal.pmed1000097 42 43	iff J, Altma	an DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The RISMA Statement. PLoS Med For more information, visit: <u>www.prisma-statement.org</u> . Page 2 of 2	6(6): e1000097.
44		For peer review only - http://bmiopen.hmi.com/site/about/quidelines.xhtml	

BMJ Open

BMJ Open

THE UTILITY OF KI-67 AS A PROGNOSTIC BIOMARKER IN PULMONARY NEUROENDOCRINE NEOPLASMS: A SYSTEMATIC REVIEW AND META-ANALYSIS.

Journal:	BMJ Open
Manuscript ID	bmjopen-2020-041961.R1
Article Type:	Original research
Date Submitted by the Author:	05-May-2021
Complete List of Authors:	Naheed, Salma; University of Southampton Faculty of Medicine, , NIHR and CRUK Experimental Cancer Medicine Center and NIHR Biomedical Research Center Southampton; Holden, Chloe; University Hospital Southampton NHS Foundation Trust, Department of Oncology, Wessex NET group ENETS Centre of Excellence Tanno, Lulu; University of Southampton Faculty of Medicine, Cancer Sciences Unit, NIHR and CRUK Experimental Cancer Medicine Center and NIHR Biomedical Research Center Southampton Pattini, Linda; Polytechnic of Milan Department of Electronics Information and Bioengineering, Department of Electronics, Information Trust Green, Bryan; University Hospital Southampton NHS Foundation Trust, Department of Pathology, Wessex NET group ENETS Centre of Excellence Jaynes, Eleanor; University Hospital Southampton NHS Foundation Trust, Department of Cellular Pathology, Wessex NET group ENETS Centre of Excellence Cave, Judith; University Hospital Southampton NHS Foundation Trust, Department of Cellular Pathology, Wessex NET group ENETS Centre of Excellence Cave, Judith; University Hospital Southampton NHS Foundation Trust, Department of Oncology, Wessex NET group ENETS Centre of Excellence Ottensmeier, Christian H. ; University of Southampton, Cancer Sciences Unit, NIHR and CRUK Experimental Cancer Medicine Center and NIHR Biomedical Research Center Southampton Pelosi, Giuseppe ; University of Milan, Department of Oncology and Hemato-Oncology
Primary Subject Heading :	Oncology
Secondary Subject Heading:	Oncology
Keywords:	Respiratory tract tumours < THORACIC MEDICINE, Pathology < NATURAL SCIENCE DISCIPLINES, Endocrine tumours < DIABETES & ENDOCRINOLOGY

1 2 3 4 5 6 7 8 9	SCHOLARONE [™] Manuscripts
10 11 12 13 14 15 16 17	
18 19 20 21 22 23 24 25 26	
27 28 29 30 31 32 33 34 35	
36 37 38 39 40 41 42 43 44	
45 46 47 48 49 50 51 52 53	
54 55 56 57 58 59 60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

review only

THE UTILITY OF KI-67 AS A PROGNOSTIC BIOMARKER IN PULMONARY NEUROENDOCRINE NEOPLASMS: A SYSTEMATIC REVIEW AND META-ANALYSIS.

Salma Naheed ¹, Chloe Holden ², Lulu Tanno ¹, Pattini L³, Neil Pearce⁴, Bryan Green⁵ Eleanor Jaynes⁵, Judith Cave², Christian Ottensmeier¹, Giuseppe Pelosi⁶

¹ Cancer Sciences Unit, Faculty of Medicine, NIHR and CRUK Experimental Cancer Medicine Center and NIHR Biomedical Research Center Southampton; University of Southampton, Somers Cancer Research Building, University Hospital Southampton, Tremona Road, Southampton, UK

² Department of Oncology, Wessex NET group ENETS Centre of Excellence, University Hospital Southampton, Tremona Road, Southampton, UK

³ Department of Electronics, Information and Bioengineering, Politecnico of Milan, Milan, Italy

⁴ Department of Surgery, Wessex NET group ENETS Centre of Excellence, University Hospital Southampton, Tremona Road, Southampton, UK

⁵ Department of Cellular Pathology, Wessex NET group ENETS Centre of Excellence, University Hospital Southampton, Tremona Road, Southampton, UK

⁶ Department of Oncology and Hemato-Oncology, University of Milan, and Inter-Hospital Pathology Division, IRCCS Multimedica, Milan, Italy

Corresponding Author: Salma Naheed, s.naheed@soton.ac.uk

Word Count: 2915

ABSTRACT

Objectives: Ki-67, a marker of cellular proliferation, is associated with prognosis across a wide range of tumours including gastroenteropancreatic neuroendocrine neoplasms, lymphoma, urothelial tumours and breast carcinomas. Its omission from the classification system of pulmonary neuroendocrine neoplasms is controversial. This systematic review sought to assess whether Ki-67 is a prognostic biomarker in lung neuroendocrine neoplasms (NENs) and if feasible, proceed to a meta-analysis.

Research Design and Methods: Medline (Ovid), Embase, Scopus and the Cochrane library were searched for studies published prior to 28 February 2019 and investigating the role of Ki-67 in lung NENs. Eligible studies were those that included more than 20 patients and provided details of survival outcomes, namely hazard ratios with confidence intervals according to Ki-67 percentage. Studies not available as a full text or without an English manuscript were excluded. This study was prospectively registered with PROSPERO, number CRD42018093389.

Results: Of 11814 records identified, 7 studies met the inclusion criteria. These retrospective studies provided data for 1268 patients (693 TC, 281 AC, 94 LCNEC and 190 SCLC) and a meta-analysis was carried out to estimate a pooled effect. Random effects analyses demonstrated an association between a high Ki-67 index and poorer overall survival (HR of 2.02, 95% CI 1.16 – 3.52) and recurrence free survival (HR 1.42; 95% CI 1.01-2.00).

Conclusion: This meta-analysis provides evidence that high Ki-67 labelling indices are associated with poor clinical outcomes for patients diagnosed with pulmonary NENs. This study is subject to inherent limitations, but it does provide valuable insights regarding the use of the biomarker Ki-67, in a rare tumour.

Prospero registration: CRD42018093389

Strengths and Limitations of this study

This systematic review and meta-analysis provides a comprehensive synopsis of the literature published up to February 2019.

The protocol adheres to PRISMA guidelines, and was published in the BMJ Open ensuring transparency.

<text> Heterogeneity in methodologies, diverse cohort sizes and types and variety of endpoints considered may limit comparison across studies.

INTRODUCTION

Bronchopulmonary neuroendocrine neoplasms (NENs) encompass a rare group of malignancies which exhibit considerable diversity and behave in an extremely heterogenous manner. Pulmonary NENs are classified through a combination of morphological neuroendocrine characteristics together with additional histological parameters by the 2015 World Health Organisation (WHO) classification.(1) This classification separates pulmonary NENs into four distinct groups ranging from typical and atypical carcinoids to large cell neuroendocrine carcinomas (LCNECs) and small cell lung carcinomas (SCLCs). Typical carcinoids (TC) are well differentiated, slow growing, indolent tumours which rarely metastasize. By way of contrast, SCLCs are aggressive, poorly differentiated tumours which have frequently metastasized at the point of presentation. Clinical outcomes are also markedly different; the 10-year survival for TCs is reported to be 82-87%, whilst the prognosis for untreated metastatic small cell lung cancer is 6-12 weeks.(2–4)

Originally identified in the 1980s by Gerdes *et al*, the DNA binding nuclear protein, Ki-67, is expressed during all phases of the cell cycle barring the rest phase (G_0).(5) *MKI67*, the gene which encodes the Ki-67 protein is located on chromosome 10q26.(6) Whilst a number of studies initially implicated Ki-67 in ribosomal RNA synthesis, more recent evidence suggests its main role is as a biological surfactant to disperse mitotic chromosomes.(7) In the setting of malignancy, Ki-67 has become established as a robust biomarker of cellular proliferation given its characteristic property of being rapidly degraded during anaphase and telophase with a short half life of 1 to 1.5 hours. Across multiple tumour sites, numerous studies have determined an association between the Ki-67 LI and patient survival.(8–12) Furthermore, evidence in other solid tumours suggests that Ki-67 is also a useful predictive biomarker, predicting response to treatment such as chemotherapy; in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) Ki-67 LI is not only integral to grading and classification but subsequently also assists oncologists to determine how best to sequence treatments for patients.

Pulmonary NENs are classified on the basis of morphological characteristics including mitotic activity and the presence or absence of necrosis (2015 WHO classification). As outlined above, they are stratified into the well differentiated NETs (TC and atypical carcinoids [ACs]) and the poorly differentiated NECs (LCNECs and SCLCs). Despite each of these subtypes being endowed with behavioural heterogeneity, these tumours are not further sub-categorised according to tumour grade.(13) This places pulmonary NENs at odds with GEP-NENs where the Ki-67 index together with the mitotic rate are important considerations when determining the grade of disease and also significantly influences how therapies are sequenced. The updated 2019 WHO classification of digestiveNENs has progressed further, by formally recognising the heterogeneity of well differentiated NETs - a well-differentiated grade 3 NET group has been included for the first time.(14)

Whilst a number of studies have been conducted to examine the prognostic utility of Ki-67 in pulmonary NENs, its omission from the pulmonary NEN classification system remains controversial. No consensus has been established for the routine use of Ki-67 in pulmonary NENs. Nevertheless, oncologists continue to request this in the belief that this marker is predictive and/or prognostic.(15) Therefore, the primary aim of this systematic review and meta-analysis is to determine whether existing evidence supports or refutes the use of Ki-67 as a prognostic biomarker in pulmonary NENs.

METHODS

This study was prospectively registered with the International Prospective Register of Systematic Reviews (PROSPERO) website (registration number CRD42018093389) following the production of a protocol in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A copy of the PRISMA protocol is also available via the *BMJ Open*.(16)

Search strategy and selection criteria

A systematic review was conducted evaluating the prognostic relevance of the Ki-67 LI in patients with bronchopulmonary NENs. MEDLINE Ovid, Embase, the Cochrane Library and Scopus were searched to look for relevant studies published from the inception of each database to 28 February 2019. The following search terms were employed: "Ki-67", "mib-1", "neuroendocrine tumor", "carcinoid" and "small cell lung carcinoma". References of articles included in the analysis were also screened to ensure a complete dataset was available for review. An example of the full search strategy is available in Supplementary File 1.

To be eligible, studies had to provide details of prognostic outcomes (hazard ratios with confidence intervals or 5-year overall survival) in more than 20 subjects with pulmonary NENs according to Ki-67 LI. Studies which did not provide sufficient prognostic details for the pulmonary NEN cohort, studies not published in English, or not available as a full manuscript were excluded. Articles which contained only predictive outcomes were also excluded.

Two independent reviewers (SN and CH) screened the title and abstracts against the pre-defined eligibility criteria independently of each other. Where discrepancies arose, a third reviewer (GP) served as arbitrator and a collective decision was then reached. Data from the studies was extracted (SN) and reviewed (GP).

Data analysis

For each study included in the meta-analysis, the following study characteristics were extracted wherever possible: first author, year of publication, country where the study was carried out, study design, number of patients, histological subtypes, mean age, disease stage, gender distribution, length of follow-up and methodology for calculating Ki-67. Hazard ratios (HR) with 95% confidence intervals (CIs) were sought as the primary outcome measure from each study in terms of overall survival (OS), disease free survival (DFS) and recurrence free survival (RFS). Secondary outcomes for each study were five year survival rates. Disease free survival denotes the length of time between primary treatment and first relapse, whereas recurrence free survival refers to the time between primary treatment and local or regional relapse.

The Newcastle-Ottawa Scale (as recommended by the Cochrane Non-Randomised Studies Methods Working Group) was utilised to appraise the quality of studies eligible for meta-analysis.(17) This involved appraising the selection, comparability and outcome of each study with scores ranging from 0 to 9. Scores of 0-3 indicate a low quality study, 4-5 and 6-9 are considered medium and high quality respectively. Only medium and high quality studies were considered for inclusion in the meta-analysis.

Statistical analysis

The statistical analyses were performed using the RevMan 5.3 software (Cochrane Collaboration, Copenhagen, Denmark). The generic inverse variance model was employed to pool and weight hazard ratios. In order to assess the heterogeneity of results between studies, Higgins I^2 statistic was used. Where there was evidence of high levels of heterogeneity (i.e. $I^2 > 50\%$), a random effects model was utilised. It was intended to assess the risk of bias using funnel-plot visual inspections together with Begg's and Egger's test.

Role of the funding source

There was no funding source for this study. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

RESULTS

The database searches identified 11814 publications. Following the exclusion of duplicates, 8057 studies remained. 8008 articles were excluded following initial screening of titles and abstracts. The remaining 49 articles were retrieved for full text review. 42 further articles were excluded, with the main

 reason for exclusion being insufficient prognostic data to facilitate a meta-analysis. A flowchart of the study selection process is shown in Figure 1. Although the planned protocol had intended to also capture 5 year survival data, due to the heterogeneity of Ki-67 cut-offs utilised and data presentation via Kaplan Meier curves, it was not possible to present this in a meaningful way. This was due to the 5 year survival estimates not being reported in all studies and could only be detected through Kaplan Meier plots.

Study characteristics and quality evaluation

Seven papers, published between 2013 and 2018 including 1268 patients (693 TC, 281 AC, 94 LCNEC and 190 SCLC) fulfilled the inclusion criteria for meta-analysis.(18–24) All included studies were retrospective and observational in nature, with no prospective studies identified. The cohort sizes varied between 82 and 399 subjects. Only one study (Rindi *et al*) was inclusive of the full range of pulmonary NENs with most studies only including the well-differentiated NETs (typical and atypical carcinoids). Four of the studies included Italian cohorts, with France, Brazil, Finland and the UK each contributing a single study. The majority of studies used the MIB-1 antibody (4 of 7), although not all studies provided this information.

The majority (76.8%) of the patients had well-differentiated tumours (either in the form TC or AC) with only a minority (23.1%) having poorly differentiated NECs. 51% of the participants were female. The age range of participants varied between 15 and 83 years with one study failing to provide this information. Three studies did not report data for tumour stage. Across the remaining four studies, the majority of participants were noted to have early stage disease (54.3% of patients had stage I disease, 15.5% stage II, 14.2% stage III, 13.8% stage IV, 4.2% stage X). Median length of follow-up ranged between 9.6 and 70 months. The population characteristics of studies included in the meta-analysis are summarised in Table 1.

Quality evaluation revealed that the studies included in the meta-analysis were of an overall good quality. The median Newcastle-Ottawa Scale score was seven, with three papers scoring seven and eight each and one scoring six [Table 2]. Five and three studies made hazard ratio and confidence interval data available for OS and RFS respectively.

Meta-analysis of overall survival

In the meta-analysis of overall survival, five studies were included (Cusumano *et al* published a death HR, whilst Vesterinen *et al* offered a HR for disease specific mortality – both were deemed to be surrogate markers of OS).(17,18) Hazard ratios derived from univariate analyses were considered for meta-analysis over their multivariate counterparts in an effort to limit the heterogeneity resulting from

how hazard ratios are derived. The heterogeneity was high: $I^2 = 69\%$. This necessitated use of a random effects model. The pooled HR for Ki-67 was 2.02 (95% CI 1.16 – 3.52) with a p-value of 0.01 [Figure 2].

Meta-analysis of recurrence free survival

In the meta-analysis of recurrence free survival (RFS), three studies were available (in one recurrence HR was available whilst a second study provided a time to progression HR – both were considered to be surrogate markers of RFS). Once again, the heterogeneity was high ($I^2 = 89\%$) and therefore a random effects model was appropriate. The pooled HR was 1.42 (95% CI 1.01-2.00; p 0.04) [Figure 3].

Risk of bias

Despite the intention to assess the risk of bias using funnel-plot visual inspections, Begg's and Egger's test, this was not feasible due to the low number of studies included in the meta-analysis.

DISCUSSION

Prognostic biomarkers and tools play an important role in oncological management and decision making processes. In pulmonary NENs the dearth of prognostic biomarkers is notable and therefore oncologists often request Ki-67 indices in order to assist in therapeutic decisions despite the fact this has not been formally adopted. The primary aim of this study was to evaluate whether existing Ki-67 LI is associated with prognosis in pulmonary NENs as has been demonstrated in numerous other tumour types (e.g. GEP-NENs, urothelial carcinomas, breast cancer, lymphoma and lung cancer).

Ki-67 is most frequently evaluated immunohistochemically on paraffin sections using the MIB-1 antibody. Scoring is generally formulated by the percentage of tumour cells stained positively to the antigen (also known as the labelling index). Several methods are available to evaluate the Ki-67 labelling index (LI), including digital image analysis, eyeball estimation and manual counting. In digestive NENs, the method currently considered 'gold standard' is to evaluate the area with the most dense Ki-67 staining (i.e. histological 'hotspots') and to subsequently manually count a minimum of 500 cells, with best practice being to count 2000 cells or 2mm².(25,26) Manual counting is subject to limitations - not only can it become tedious, but it is time-consuming as counting 2000 cells can take approximately 40 minutes to complete. Utilising camera captured printed images reduces issues with inter-observer variability, although the issue of intra-tumoural heterogeneity remains as selecting which tumour area will be subjected to counting can be difficult to establish with consistency.(27) Therefore, some pathologists resort to eyeball estimations, resulting in poor reproducibility and inter-observer

BMJ Open

variability relating to the pathologists experience.(28) Digital image analysis has been heralded as a means of deriving uniformity, but it is not currently widely employed as a result of a number of obstacles including technical issues (e.g. overcounting unwanted cells and underestimating negative cells) as well as its current lack of worldwide availability.

This meta-analysis provides tentative evidence demonstrating that high Ki-67 indices are associated with a 40% greater risk of recurrence amongst patients diagnosed with pulmonary NENs. This risk appears to be further exaggerated when considering overall survival where patients with a high Ki-67 have double the risk of death in comparison with patients with a lower Ki-67 LI. The strength of the association between Ki-67 LI and prognosis was only evaluated in studies that calculated hazard ratios using univariate analyses. As a result, no attempt has been made to account for confounding factors (such as stage, grade, and mitotic index).

One of the major pitfalls of including Ki-67 in the classification of pulmonary NENs has in establishing the most appropriate thresholds or cut-offs that should be utilised when grading tumours. In the main, Ki-67 has not been used as a linear biomarker within the whole pulmonary NEN cohort, instead focusing on its utility within each categorical histological subtype. Whilst categorising NENs by grade is helpful in establishing management plans, it is likely that proliferative markers (such as Ki-67 and mitotic index) are continuous rather than categorical variables. Therefore, there may not be a single or absolute optimal cut off value to categorise tumours into distinct entities and a pragmatic approach is likely to be needed. In order to facilitate clinical clarity, it would be preferable to use the same thresholds as are utilised in GEP-NETs and any future studies should attempt to clarify this further. However, it is unclear whether attempting to implement a similar grading system in pulmonary NENs as GEP NENs does a disservice to the fundamental biological diversity between the two different tumour sites.(29) Examples of this diversity include the variability of genetic alterations seen as well as the differing rates of associated syndromes and hormone expression . (30-35)

Unfortunately only two studies involving SCLC and high grade neuroendocrine carcinomas of the lung were available. It is important to clarify that Ki-67 is not likely to be useful in subtyping these tumours prognostically. A number of biomarkers have been identified which may have greater utility in these patients. Nevertheless further research into Ki-67 is required in these tumour groups with such little evidence, especially in light of the fact that in GEP-NENs there is good evidence to suggest that Ki-67 is contributory with a cut-off of 55%.(36)

As with all studies, this meta-analysis is also subject to inherent limitations. None of the studies included in the meta-analyses were prospective in design; retrospective analyses are prone to error through issues with selection bias and reporting. Secondly, studies with a variety of endpoints (e.g. RFS analyses included studies where the endpoint was DFS and time to progression analyses etc.), diverse cohort sizes, differences in the dilution of the primary antibody as well as variable Ki-67 cut-offs have all been amalgamated. Whilst some degree of heterogeneity is always to be expected, it diminishes the validity of the combined data-set and subsequent results. This is reflected in the I² statistics noted across both meta-analyses.

This study also preferentially utilised univariate analyses. Whilst multivariate analyses can be significantly distorted by differing in their approach to modelling or prognostic factors, univariate analyses fail to account for confounding variables. Furthermore, given the small number of studies identified as suitable for inclusion in this meta-analysis, it is clear that future international multi-centre efforts are needed to develop studies which are prospective with large cohorts to clarify whether Ki-67 labelling index is truly a prognostic biomarker in the setting of bronchopulmonary neuroendocrine neoplasms.

CONCLUSIONS

Although it is difficult to draw definitive conclusions, this meta-analysis of over 1250 patients with pulmonary NENs indicates that a high Ki-67 LI is associated with an adverse prognosis. Whilst these findings are subject to a number of limitations, they provide a valuable insight into a rare tumour and should be considered when producing new guidelines regarding the use of Ki-67 in pulmonary NENs.

Conflict of interest statement: The authors have declared no competing interests.

Funding Statement: This research is an academic spontaneous study, which received no specific grant from any funding agency, commercial or not-for profit sectors.

SN's postgraduate studies are funded by PLANETS Cancer Charity, a not for profit organisation which had no role in developing this protocol or performing the meta-analysis.

Patient and public involvement: Patients and the public were not involved in the development of this systematic review or meta-analysis.

Data Availability Statement: All data relevant to the study are included in the article or uploaded as supplementary information.

Ethics Statement: Given that this is a systematic review of existing literature, ethical approval is not required.

Figure Legends:

Figure 1: Study Selection

Figure 2: Forest plot of studies evaluating the association between Ki-67 expression and overall survival in pulmonary neuroendocrine neoplasms.

CI = confidence interval

Figure 3: Forest plot of studies evaluating the association between Ki-67 expression and recurrence free survival in pulmonary neuroendocrine neoplasms.

CI = confidence interval.

REFERENCES

- 1. Travis WD Burke AP, Marx A, Nicolson AG. BE. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. *Int Agency Res Cancer.* 2015.
- 2. Asamura H, Kameya T, Matsuno Y, Noguchi M, Tada H, Ishikawa Y, et al. Neuroendocrine neoplasms of the lung: A prognostic spectrum. *J Clin Oncol.* 2006;24(1):70–6.
- Ducrocq X, Thomas P, Massard G, Barsotti P, Giudicelli R, Fuentes P, et al. Operative risk and prognostic factors of typical bronchial carcinoid tumors. *Ann Thorac Surg*. 1998;65(5):1410–4.
- Soga J, Yakuwa Y. Bronchopulmonary carcinoids: An analysis of 1,875 reported cases with special reference to a comparison between typical carcinoids and atypical varieties. *Ann Thorac Cardiovasc Surg.* 1999;5(4):211–9.
- Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. *Int J cancer*. 1983 ;31(1):13–20.
- 6. Menon SS, Guruvayoorappan C, Sakthivel KM, Rasmi RR. Ki-67 protein as a tumour proliferation marker. *Clin Chim Acta*. 2019;491:39–45.
- 7. Cuylen S, Blaukopf C, Politi AZ et al. Ki-67 acts as a biological surfactant to disperse mitotic chromosomes. *Nature*. 2016; 535(7611):308-12.
- de Azambuja E, Cardoso F, de Castro G, Colozza M, Mano MS, Durbecq V, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients. *Br J Cancer*. 2007;96(10):1504–13.
- Khor L-Y, Bae K, Paulus R, Al-Saleem T, Hammond ME, Grignon DJ, et al. MDM2 and Ki-67 Predict for Distant Metastasis and Mortality in Men Treated With Radiotherapy and Androgen Deprivation for Prostate Cancer: RTOG 92-02. *J Clin Oncol*. 2009;27(19):3177–84.
- Jann H, Roll S, Couvelard A, Hentic O, Pavel M, Müller-Nordhorn J, et al. Neuroendocrine tumors of midgut and hindgut origin: Tumor-node-metastasis classification determines clinical outcome. *Cancer*. 2011;117(15):3332–41.
- 11. Klöppel G, La Rosa S. Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms. *Virchows Arch*. 2018;472(3):341–9.
- Taylor SR, Ewings SM, Jaynes E, Tilley C, Ellis SG, Armstrong T, et al. The assessment of Ki-67 as a prognostic marker in neuroendocrine tumours: A systematic review and meta-analysis. *J Clin Pathol.* 2016;69(7):612–8.
- 13. Pelosi G, Bianchi F, Hofman P, Pattini L, Ströbel P, Calabrese F. Recent advances in the

1 2		
2 3 4		molecular landscape of lung neuroendocrine tumors. Expert Rev Mol Diagn. 2019;19(4):1–17.
5 6 7 8 9	14.	Klimstra D, Kloppel G, La Rosa Salas B et al. Classification of neuroendocrine neoplasms of the digestive system. In <i>WHO Classification of Tumours. Digestive System Tumours.</i> 2019 (5 th ed):16-21.
10 11 12 13 14	15.	Marchevsky AM, Hendifar A, Walts AE. The use of Ki-67 labeling index to grade pulmonary well-differentiated neuroendocrine neoplasms: current best evidence. <i>Mod Pathol</i> . 2018;31(10):1523–31.
15 16 17	16.	Naheed S, Holden C, Tanno L, Jaynes E, Cave J <i>et al</i> . The Utility Of Ki-67 As A Prognostic Biomarker In Pulmonary Neuroendocrine Tumours : <i>BMJ Open;</i> 2019 Aug 24;9(8):e031531.
18 19 20 21	17.	Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. <i>Eur J Epidemiol</i> . 2010 ;25(9):603–5.
22 23 24 25 26	18.	Cusumano G, Fournel L, Strano S, Damotte D, Charpentier MC, Galia A, et al. Surgical Resection for Pulmonary Carcinoid: Long-Term Results of Multicentric Study-The Importance of Pathological N Status, More Than We Thought. <i>Lung.</i> 2017; 195(6):789–98.
27 28 29 30 31	19.	Vesterinen T, Mononen S, Salmenkivi K, Mustonen H, Ilonen I, Knuuttila A, et al. Clinicopathological indicators of survival among patients with pulmonary carcinoid tumor. <i>Acta</i> <i>Oncol (Madr)</i> . 2018 57(8):1109–1116.
32 33 34	20.	Marchio C, Gatti G, Massa F, Bertero L, Filosso P, Pelosi G, et al. Distinctive pathological and clinical features of lung carcinoids with high proliferation index. <i>Virchows Arch.</i> 471(6):713–20.
35 36 37 38 39	21.	Filosso PL, Oliaro A, Ruffini E, Bora G, Lyberis P, Asioli S, et al. Outcome and prognostic factors in bronchial carcinoids: A single-center experience. <i>J Thorac Oncol</i> . 2013;8(10):1282–8.
40 41 42 43 44	22.	Clay V, Papaxoinis G, Sanderson B, Valle JW, Howell M, Lamarca A, et al. Evaluation of diagnostic and prognostic significance of Ki-67 index in pulmonary carcinoid tumours. <i>Clin Transl Oncol</i> . 2017;19(5):579–86.
45 46 47 48 49	23.	Rindi G, Klersy C, Inzani F. A three tier grading system based on Ki-67 index, mitotic count and necrosis with cut-offs specifically generated for lung neuroendocrine tumors is prognostically effective and accurate. <i>Neuroendocrinology</i> . 2014;99:251.
50 51 52 53 54 55 56	24.	de M Rego Juliana Florinda, de Medeiros RSS, Braghiroli MI, Galvao B, Neto JEB, Munhoz RR, et al. Expression of ERCC1, Bcl-2, Lin28a, and Ki-67 as biomarkers of response to first- line platinum-based chemotherapy in patients with high-grade extrapulmonary neuroendocrine carcinomas or small cell lung cancer. <i>Ecancer.</i> 2017; 11:767.
57 58 59 60	25.	Fabbri A, Cossa M, Sonzogni A, Papotti M, Righi L, Gatti G, et al. Ki-67 labeling index of neuroendocrine tumors of the lung has a high level of correspondence between biopsy samples and surgical specimens when strict counting guidelines are applied. <i>Virchows Arch</i> .


2017;470(2):153-64.


- 26. Pelosi G, Rindi G, Travis WD, Papotti M. Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice. *J Thorac Oncol.* 2014;9(3):273–84.
- 27. Reid MD, Bagci P, Ohike N, Saka B, Erbarut Seven I, Dursun N, et al. Calculation of the Ki67 index in pancreatic neuroendocrine tumors: a comparative analysis of four counting methodologies. *Mod Pathol.* 2015;28(5):686–94.
- Klimstra DS, Modlin IR, Adsay NV, Chetty R, Deshpande V, Gönen M, et al. Pathology Reporting of Neuroendocrine Tumors: Application of the Delphic Consensus Process to the Development of a Minimum Pathology Data Set. *Am J Surg Pathol*. 2010;34(3):300–13.
- 29. Kasajima A, Kloppel G. Neuroendocrine neoplasms of lung, pancreas and gut: a morphologybased comparison. *Endocrine-Related Cancer.* 2020; 27(11):R417-R432.
- 30. Jiao Y, Shi C, Edil BH et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumours. *Science*. 2011; 331: 1199-1203.
- 31. Simbolo M, Barbi S, Fassan M et al. Gene expression profiling of lung atypical carcinoids and large cell neuroendocrine carcinomas identifies three transcrimptomic subtypes with specific genomic alterations. *J Thor Onc.* 2019; 14: 1651-1661.
- 32. Swarts DR, Scarpa A, Corbo V et al. MEN1 gene mutation and reduced expression are associated with poor prognosis in pulmonary carcinoids. *J Clinical Endocrinology and Metabolism* 2014; 99: E374-E378.
- Alcala N, Leblay N, Gabriel AAG et al. Integrative and comparitive genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids. *Nature Communications*. 2019; 10: 3407.
- 34. Gustaffson BI, Kidd M, Chan A et al. Bronchopulmonary neuroendocrine tumors. *Cancer.* 2008; 113:5-21.
- Pape UF, Jann H, Muller-Nordhorn J et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumours. *Cancer.* 2008; 113:256-265.
- Sorbye H, Welin S, Langer SW et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. *Ann Oncol.* 2013; 24(1):152-160.

tor peer teriew only

Author (Year) 1 2 3 Cusumano 4 et al (2017)	Trial Design (study centres) Retrospective multicentre	Number of Subjects 195	Histological subtypes TC (159); AC (36)	Age Range 52.94 (TC); 60.16 (AC)	Gender M:F 89:106	I = 163; II = 16; III = 16;	Optifiody NR	Methodology for calculating Ki-67 NR	Median length of follow-up (months) 75 (mean)	5/bmtogen-2020-041961 (%) NR 1961 (%)	Outcome measure OS (Death HR)	Hazard Ratio (95% CI) from univariate analyses 1.07 (0.97- 1.17)	Page 18 of 23
5 6 7	study (France, Italy)			[mean values]		IV = 0				ы В		0.97 (1.01– 1.2)	
8 _{Rego} et al 9 (2017) 10 11	Retrospective, multicentre study (Brazil)	82	SCLC (82)	35-81 (mean 59)	48:34	I = 0; II = 0; III = 6; IV = 76	MIB-1 (1:1000)	Hotspot method; otherwise not specified	10.3	3 March 2022. Do		1.15 (0.70- 1.89)	
12 _{Marchio} et 13 al (2017) 14 15	Retrospective multicentre study (Italy)	239	TC (171); AC (68)	NR	100:139	NR	NR	Manual counting of >1000 cells	NR	4 wnloaded 1	OS	4.31 (1.624- 11.45) 3.994 (1.58-	
16 17										from	IIP	3.994 (1.58- 10)	
18 Filosso et al 19 (2013) 20 21 22	Retrospective, single centre study (Italy)	126 [NB 110 included in Ki-67 analysis]	TC (83); AC (43). [In Ki- 67 analysis TC (79); AC (31)]	15-82 (mean 60)	52:74	I = 90; II = 18; III = 16; IV = 2; X = 1	anti–Ki-67 antibody (DAKO) not further specified	NR	60	4 Downloaded from http://bmjopen.bmj	OS	2.08 (1.02- 4.27)	
23 Rindi et al 24 ⁽²⁰¹⁴⁾ 25 26 27	Retrospective, multicentre study (Italy)	399	TC (113); AC (84); LCNEC (94); SCLC (108)	63.26 (median)	245:154	I = 183; II = 90; III = 76; IV = 17; X = 33	MIB-1 antibody	Computer assisted manual count method 500- 2000 cells	70.72			1.26 (0.84- 1.89)	
28 ^{Clay} et al 29 ⁽²⁰¹⁷⁾ 30 31 32 33	Retrospective, single centre study (UK)	94 [NB survival analysis performed on 84]	TC (75); AC (19) [NB survival analysis performed 67 TC, 17 AC patients]	21-83 (median 60.5)	39:55	NR	MIB-1 antibody (1:50)	Manual count method 500- 2000 cells in hot spot	35	com/ on April 19, 2024 by gues	RFS	1.47 (1.25- 1.74)	
34 _{Vesterinen} 35 _{et al} (2018) 36 37 38	Retrospective, single centre study (Finland)	133 (129 included in Ki-67 analysis)	TC (100); AC (33)		47:86	NR	MIB-1 antibody (1:100)	Manual and automated counting of 2000 cells	9.6	2.5 t. Protected	Disease specific mortality	10.51 (2.12- 52.13)	
₃ Jable 1: Ma	in Characteri	stics of all s	tudies inclu	ded in the m	eta-analysi	S.				by co			
4 ∱⁄I = male, F 41	=iemaie, NR =	= not record	eu, US = 0V6	erali survival,	, кн з = recu		urvival, DFS	= disease fre	e survival, l	<u> </u>		vr1.	
42						16				ight.			
43 44 45 46				For peer rev	view only - ht	tp://bmjoper	ı.bmj.com/sit	e/about/guid	lelines.xhtml				

Page 19 of 23					BMJ Open			o/bmj op Adequacy of	
Author (Year) 1 2 3	Representativenes s of cohort	Adequate definition of cases	Assessment of exposure	Outcome of interest not present at start of study	Comparibility on the basis of the design or analysis	Assessment of Outcome (death or recurrence)	Adequacy of median follow- up for outcome (>2 years)	B dequacy of B llow-up of cases (<20% or dreported)	Total Quality Score
4 5	(1 point)	(1 point)	(1 point)	(1 point)	(2 points)	(1 point)	(1 point)	0 1 (1 point) ი ა	
6 7 Cusumano et al 8 (2017) 9	${}$	Δ	λ	-	(2 points)	Δ		3 March 20	8
10 11 Rego et al 12 (2017) 13	${}$	Δ	*	-	${}$	${_{\sim}}$	-	AX 22. Downloa	6
14 15 ^{Marchio} et al 16 (2017) 17	\Rightarrow	\mathcal{A}	*	500	☆☆	\mathbf{A}	-	aded from h	7
¹⁸ _{Filosso} et al 19 20 ⁽²⁰¹³⁾ 21	\Rightarrow	${\mathbf{A}}$	${\searrow}$	64	**	\mathbf{A}	${\searrow}$	↓	8
22 Rindi et al 23 ₍₂₀₁₄₎ 24 25	${}$	Δ	λ	-	☆☆	*	λ	n.bmj.com	8
26 ^{Clay} et al (2017) 27 28	Δ	Δ	λ	-	\mathbf{A}	*	☆	on April 19	7
29 30 ^{Vesterinen et al} 31 (2018) 32 33	\$	${\not\sim}$	\$	-	**	\$	Y	Image: Arrow of the system Image: Arrow of the system <td< td=""><td>7</td></td<>	7
	ty assessment of	included stu	idies utilising th	ne (modified) N	ewcastle-Ottav	wa		. Protected by copyright	
³⁸ Scale. ³⁹ 40								by cop	
40 41 42				17	7			yright.	
43 44 45 46			For peer review	w only - http://bn	njopen.bmj.com/s	site/about/guidel	ines.xhtml		





1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 - 27 28 29 30 31 32 33	Filosso 2013 Rindi 2014 Rego 2017 Marchio 2017 Vesterinen 2018 Total (95% CI) Heterogeneity: Tau ² = 0.2	0.7324 0.3636 0 0.2311 0.2069 0 0.1398 0.2533 0 1.4609 0.498 0 2.3523 0.8168 0 0 5; Chi ² = 12.75, df = 4 (P = 0.01); F	 0 21.2% 0 27.8% 0 25.9% 0 16.3% 0 8.8% 0 100.0% 	Hazard Ratio IV, Random, 95% CI Ye 2.08 [1.02, 4.24] 200 1.26 [0.84, 1.89] 200 1.15 [0.70, 1.89] 200 4.31 [1.62, 11.44] 200 10.51 [2.12, 52.10] 200 2.02 [1.16, 3.52]	13 14 17 17	Hazard Ratio Random, 95% CI	-
 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 90 51 52 53 54 55 56 57 58 59 60 		plot of studies evaluating pendocrine neoplasms.			expression and	overall survival in	

						Hazard Ratio			lazard Ratio	~	
Study or Subgroup	log[Hazard Ratio]	SE	Total	Total	Weight	IV, Random, 95% Cl		IV, F	Random, 95%	CI	
Clay 2017	0.3853	0.0827	0	0	43.0%	1.4701 [1.2501, 1.7287]			-		
Cusumano 2017	0.0862	0.0389	0	0	46.5%	1.0900 [1.0100, 1.1764]			•		
Marchio 2017	1.3848	0.4732	0	0	10.5%	3.9940 [1.5799, 10.0972]				•	-
Total (95% CI)			0	0	100.0%	1.4202 [1.0110, 1.9951]			•		
Heterogeneity: Tau ² = Test for overall effect:		∦f=2(P∶	= 0.000	2); I² =	89%		0.05	0.2	1	5	20

Figure 3: Forest plot of studies evaluating the association between Ki-67 expression and recurrence free survival in pulmonary neuroendocrine neoplasms.

CI = confidence interval.

EXAMPLE OF FULL SEARCH STRATEGY

The systematic review will employ the following search terms for Medline OVID, and EMBASE:

Ki-67 antigen/ OR (Ki67 or Ki-67 or mib-1 or mib1).mp.

AND

neuroendocrine tumors/ or carcinoid tumor/ or carcinoma, neuroendocrine/ OR small cell lung carcinoma/ OR ((tumo?r* or neoplas* or carcinoma or cancer* or malignan*) adj3 (neuroendocrine or carcinoid or small cell)).mp. to perteries only



PRISMA 2009 Checklist

			BMJ Open 1366	Page 24 of 23
1 2	PRISMA 20	09	BMJ Open 36/ Daji Open Checklist 20	
3 4 5	Section/topic	#	Checklist item 41	Reported on page #
6 7	TITLE		9	
8	Title	1	Identify the report as a systematic review, meta-analysis, or both. $\overset{\omega}{\leq}$	1
9 10	ABSTRACT			
1 12 12	Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data source study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
1	INTRODUCTION			
1	Rationale	3	Describe the rationale for the review in the context of what is already known.	3-4
1 1 1	Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, in grventions, comparisons, outcomes, and study design (PICOS).	4
2	METHODS		o://b	
2 2 2	Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and if available, provide registration information including registration number.	4
24 2	Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5
2	Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
29		8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	5
3	Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	5
3	Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	5
3	Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	5
3 3 4	Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	5-6
4	Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	5-6
4. 4. 4.	Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including near assures of consistency (e.g., I ²) for each meta-analysis.	5-6
4 4 4	5		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml Page 1 of 2	·

Page 25 of 23



3 i

PRISMA 2009 Checklist

3 4 5	Section/topic	#	Checklist item	Reported on page #
6 7 8	Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	5-6
9 10	Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	5-6
12	RESULTS		022.	
13 14	Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	6
15 16 17	Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOs, follow-up period) and provide the citations.	6-7
18	Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	7
19 20 21	Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summare data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	6-7
22	Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	7
23 24	Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	7
25	Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	7
26 27	DISCUSSION	·	Q	
28 29	Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	7-8
30 31 32	Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	7-8
33 34	Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	9
35	FUNDING		lest.	
36 37 38	Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data; role of funders for the systematic review.	6
39 40	<i>From:</i> Moher D, Liberati A, Tetzlaff doi:10.1371/journal.pmed1000097	J, Altma	법. an DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The 무RISMA Statement. PLoS Med 유	6(6): e1000097.
41 42			For more information, visit: <u>www.prisma-statement.org</u> .	
43			Page 2 of 2	
44 45			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	
46 47				

1136/bmjopen-202

BMJ Open

BMJ Open

THE UTILITY OF KI-67 AS A PROGNOSTIC BIOMARKER IN PULMONARY NEUROENDOCRINE NEOPLASMS: A SYSTEMATIC REVIEW AND META-ANALYSIS.

1	BM1 On an
Journal:	
Manuscript ID	bmjopen-2020-041961.R2
Article Type:	Original research
Date Submitted by the Author:	22-Sep-2021
Complete List of Authors:	Naheed, Salma; University of Southampton Faculty of Medicine, , NIHR and CRUK Experimental Cancer Medicine Center and NIHR Biomedical Research Center Southampton; Holden, Chloe; University Hospital Southampton NHS Foundation Trust, Department of Oncology, Wessex NET group ENETS Centre of Excellence Tanno, Lulu; University of Southampton Faculty of Medicine, Cancer Sciences Unit, NIHR and CRUK Experimental Cancer Medicine Center and NIHR Biomedical Research Center Southampton Pattini, Linda; Polytechnic of Milan Department of Electronics Information and Bioengineering, Department of Electronics, Information Trust Green, Bryan; University Hospital Southampton NHS Foundation Trust, Department of Pathology, Wessex NET group ENETS Centre of Excellence Jaynes, Eleanor; University Hospital Southampton NHS Foundation Trust, Department of Cellular Pathology, Wessex NET group ENETS Centre of Excellence Cave, Judith; University Hospital Southampton NHS Foundation Trust, Department of Cellular Pathology, Wessex NET group ENETS Centre of Excellence Cave, Judith; University Hospital Southampton NHS Foundation Trust, Department of Oncology, Wessex NET group ENETS Centre of Excellence Ottensmeier, Christian H. ; University of Southampton, Cancer Sciences Unit, NIHR and CRUK Experimental Cancer Medicine Center and NIHR Biomedical Research Center Southampton Pelosi, Giuseppe ; University of Milan, Department of Oncology and Hemato-Oncology
Primary Subject Heading :	Oncology
Secondary Subject Heading:	Oncology
Keywords:	Respiratory tract tumours < THORACIC MEDICINE, Pathology < NATURAL SCIENCE DISCIPLINES, Endocrine tumours < DIABETES & ENDOCRINOLOGY

1 2 3 4 5 6 7 8 9	SCHOLARONE [™] Manuscripts
10 11 12 13 14 15 16 17	
18 19 20 21 22 23 24 25 26 27	
27 28 29 30 31 32 33 34 35 36	
37 38 39 40 41 42 43 44 45	
46 47 48 49 50 51 52 53 54	
55 56 57 58 59 60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

RELEX ONL

THE UTILITY OF KI-67 AS A PROGNOSTIC BIOMARKER IN PULMONARY NEUROENDOCRINE NEOPLASMS: A SYSTEMATIC REVIEW AND META-ANALYSIS.

Salma Naheed ¹, Chloe Holden ², Lulu Tanno ¹, Pattini L³, Neil Pearce⁴, Bryan Green⁵ Eleanor Jaynes⁵, Judith Cave², Christian Ottensmeier¹, Giuseppe Pelosi⁶

¹ Cancer Sciences Unit, Faculty of Medicine, NIHR and CRUK Experimental Cancer Medicine Center and NIHR Biomedical Research Center Southampton; University of Southampton, Somers Cancer Research Building, University Hospital Southampton, Tremona Road, Southampton, UK

² Department of Oncology, Wessex NET group ENETS Centre of Excellence, University Hospital Southampton, Tremona Road, Southampton, UK

³ Department of Electronics, Information and Bioengineering, Politecnico of Milan, Milan, Italy

⁴ Department of Surgery, Wessex NET group ENETS Centre of Excellence, University Hospital Southampton, Tremona Road, Southampton, UK

⁵ Department of Cellular Pathology, Wessex NET group ENETS Centre of Excellence, University Hospital Southampton, Tremona Road, Southampton, UK

⁶ Department of Oncology and Hemato-Oncology, University of Milan, and Inter-Hospital Pathology Division, IRCCS Multimedica, Milan, Italy

Corresponding Author: Salma Naheed, s.naheed@soton.ac.uk

Word Count: 2915

ABSTRACT

Objectives: Ki-67, a marker of cellular proliferation, is associated with prognosis across a wide range of tumours including gastroenteropancreatic neuroendocrine neoplasms, lymphoma, urothelial tumours and breast carcinomas. Its omission from the classification system of pulmonary neuroendocrine neoplasms is controversial. This systematic review sought to assess whether Ki-67 is a prognostic biomarker in lung neuroendocrine neoplasms (NENs) and if feasible, proceed to a meta-analysis.

Research Design and Methods: Medline (Ovid), Embase, Scopus and the Cochrane library were searched for studies published prior to 28 February 2019 and investigating the role of Ki-67 in lung NENs. Eligible studies were those that included more than 20 patients and provided details of survival outcomes, namely hazard ratios with confidence intervals according to Ki-67 percentage. Studies not available as a full text or without an English manuscript were excluded. This study was prospectively registered with PROSPERO, number CRD42018093389.

Results: Of 11814 records identified, 7 studies met the inclusion criteria. These retrospective studies provided data for 1268 patients (693 TC, 281 AC, 94 LCNEC and 190 SCLC) and a meta-analysis was carried out to estimate a pooled effect. Random effects analyses demonstrated an association between a high Ki-67 index and poorer overall survival (HR of 2.02, 95% Cl 1.16 – 3.52) and recurrence free survival (HR 1.42; 95% Cl 1.01-2.00).

Conclusion: This meta-analysis provides evidence that high Ki-67 labelling indices are associated with poor clinical outcomes for patients diagnosed with pulmonary NENs. This study is subject to inherent limitations, but it does provide valuable insights regarding the use of the biomarker Ki-67, in a rare tumour.

Prospero registration: CRD42018093389

Strengths and Limitations of this study

This systematic review and meta-analysis provides a comprehensive synopsis of the literature published up to February 2019.

The protocol adheres to PRISMA guidelines, and was published in the BMJ Open ensuring transparency.

<text> Heterogeneity in methodologies, diverse cohort sizes and types and variety of endpoints considered may limit comparison across studies.

INTRODUCTION

Bronchopulmonary neuroendocrine neoplasms (NENs) encompass a group of malignancies which exhibit considerable diversity and behave in an extremely heterogenous manner. Pulmonary NENs are classified through a combination of morphological neuroendocrine characteristics together with additional histological parameters by the 2015 World Health Organisation (WHO) classification.(1) This classification separates pulmonary NENs into four distinct groups ranging from typical and atypical carcinoids to large cell neuroendocrine carcinomas (LCNECs) and small cell lung carcinomas (SCLCs). Typical carcinoids (TC) are well differentiated, slow growing, indolent tumours which rarely metastasize. By way of contrast, SCLCs are aggressive, poorly differentiated tumours which have frequently metastasized at the point of presentation. Clinical outcomes are also markedly different; the 10-year survival for TCs is reported to be 82-87%, whilst the prognosis for untreated metastatic small cell lung cancer is 6-12 weeks.(2–4)

Originally identified in the 1980s by Gerdes *et al*, the DNA binding nuclear protein, Ki-67, is expressed during all phases of the cell cycle barring the rest phase (G_0).(5) *MKI67*, the gene which encodes the Ki-67 protein is located on chromosome 10q26.(6) Whilst a number of studies initially implicated Ki-67 in ribosomal RNA synthesis, more recent evidence suggests its main role is as a biological surfactant to disperse mitotic chromosomes.(7) In the setting of malignancy, Ki-67 has become established as a robust biomarker of cellular proliferation given its characteristic property of being rapidly degraded during anaphase and telophase with a short half life of 1 to 1.5 hours. Across multiple tumour sites, numerous studies have determined an association between the Ki-67 LI and patient survival.(8–12) Furthermore, evidence in other solid tumours suggests that Ki-67 is also a useful predictive biomarker, predicting response to treatment such as chemotherapy; in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) Ki-67 LI is not only integral to grading and classification but subsequently also assists oncologists to determine how best to sequence treatments for patients.

Pulmonary NENs are classified on the basis of morphological characteristics including mitotic activity and the presence or absence of necrosis (2015 WHO classification). As outlined above, they are stratified into the well differentiated NETs (TC and atypical carcinoids [ACs]) and the poorly differentiated NECs (LCNECs and SCLCs). Despite each of these subtypes being endowed with behavioural heterogeneity, these tumours are not further sub-categorised according to tumour grade.(13) This places pulmonary NENs at odds with GEP-NENs where the Ki-67 index together with the mitotic rate are important considerations when determining the grade of disease and also significantly influences how therapies are sequenced. The updated 2019 WHO classification of digestive NENs has progressed further, by formally recognising the heterogeneity of grade 3 NET group has been included for the first time differentiated them from their poorlu differentiated counterparts.(14)

Whilst a number of studies have been conducted to examine the prognostic utility of Ki-67 in pulmonary NENs, its omission from the pulmonary NEN classification system remains controversial. No consensus has been established for the routine use of Ki-67 in pulmonary NENs. Nevertheless, oncologists continue to request this in the belief that this marker is predictive and/or prognostic.(15) Therefore, the primary aim of this systematic review and meta-analysis is to determine whether existing evidence supports or refutes the use of Ki-67 as a prognostic biomarker in pulmonary NENs.

METHODS

This study was prospectively registered with the International Prospective Register of Systematic Reviews (PROSPERO) website (registration number CRD42018093389) following the production of a protocol in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A copy of the PRISMA protocol is also available via the *BMJ Open*.(16)

Search strategy and selection criteria

A systematic review was conducted evaluating the prognostic relevance of the Ki-67 LI in patients with bronchopulmonary NENs. MEDLINE Ovid, Embase, the Cochrane Library and Scopus were searched to look for relevant studies published from the inception of each database to 28 February 2019. The following search terms were employed: "Ki-67", "mib-1", "neuroendocrine tumor", "carcinoid" and "small cell lung carcinoma". References of articles included in the analysis were also screened to ensure a complete dataset was available for review. An example of the full search strategy is available in Supplementary File 1.

To be eligible, studies had to provide details of prognostic outcomes (hazard ratios with confidence intervals or 5-year overall survival) in more than 20 subjects with pulmonary NENs according to Ki-67 LI. Studies which did not provide sufficient prognostic details for the pulmonary NEN cohort, studies not published in English, or not available as a full manuscript were excluded. Articles which contained only predictive outcomes were also excluded.

Two independent reviewers (SN and CH) screened the title and abstracts against the pre-defined eligibility criteria independently of each other. Where discrepancies arose, a third reviewer (GP) served as arbitrator and a collective decision was then reached. Data from the studies was extracted (SN) and reviewed (GP).

Data analysis

For each study included in the meta-analysis, the following study characteristics were extracted wherever possible: first author, year of publication, country where the study was carried out, study design, number of patients, histological subtypes, mean age, disease stage, gender distribution, length of follow-up and methodology for calculating Ki-67. Hazard ratios (HR) with 95% confidence intervals (CIs) were sought as the primary outcome measure from each study in terms of overall survival (OS), disease free survival (DFS) and recurrence free survival (RFS). Secondary outcomes for each study were five year survival rates. Disease free survival denotes the length of time between primary treatment and first relapse, whereas recurrence free survival refers to the time between primary treatment and local or regional relapse.

The Newcastle-Ottawa Scale (as recommended by the Cochrane Non-Randomised Studies Methods Working Group) was utilised to appraise the quality of studies eligible for meta-analysis.(17) This involved appraising the selection, comparability and outcome of each study with scores ranging from 0 to 9. Scores of 0-3 indicate a low quality study, 4-5 and 6-9 are considered medium and high quality respectively. Only medium and high quality studies were considered for inclusion in the meta-analysis.

Statistical analysis

The statistical analyses were performed using the RevMan 5.3 software (Cochrane Collaboration, Copenhagen, Denmark). The generic inverse variance model was employed to pool and weight hazard ratios. In order to assess the heterogeneity of results between studies, Higgins I² statistic was used. Where there was evidence of high levels of heterogeneity (i.e. $I^2 > 50\%$), a random effects model was utilised. It was intended to assess the risk of bias using funnel-plot visual inspections together with Begg's and Egger's test.

Role of the funding source

There was no funding source for this study. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

RESULTS

The database searches identified 11814 publications. Following the exclusion of duplicates, 8057 studies remained. 8008 articles were excluded following initial screening of titles and abstracts. The

 remaining 49 articles were retrieved for full text review. 42 further articles were excluded, with the main reason for exclusion being insufficient prognostic data to facilitate a meta-analysis. A flowchart of the study selection process is shown in Figure 1. Although the planned protocol had intended to also capture 5 year survival data, due to the heterogeneity of Ki-67 cut-offs utilised and data presentation via Kaplan Meier curves, it was not possible to present this in a meaningful way. This was due to the 5 year survival estimates not being reported in all studies and could only be detected through Kaplan Meier plots.

Study characteristics and quality evaluation

Seven papers, published between 2013 and 2018 including 1268 patients (693 TC, 281 AC, 94 LCNEC and 190 SCLC) fulfilled the inclusion criteria for meta-analysis.(18–24) All included studies were retrospective and observational in nature, with no prospective studies identified. The cohort sizes varied between 82 and 399 subjects. Only one study (Rindi *et al*) was inclusive of the full range of pulmonary NENs with most studies only including the well-differentiated NETs (typical and atypical carcinoids). Four of the studies included Italian cohorts, with France, Brazil, Finland and the UK each contributing a single study. The majority of studies used the MIB-1 antibody (4 of 7), although not all studies provided this information.

The majority (76.8%) of the patients had well-differentiated tumours (either in the form TC or AC) with only a minority (23.1%) having poorly differentiated NECs. 51% of the participants were female. The age range of participants varied between 15 and 83 years with one study failing to provide this information. Three studies did not report data for tumour stage. Across the remaining four studies, the majority of participants were noted to have early stage disease (54.3% of patients had stage I disease, 15.5% stage II, 14.2% stage III, 13.8% stage IV, 4.2% stage X). Median length of follow-up ranged between 9.6 and 70 months. The population characteristics of studies included in the meta-analysis are summarised in Table 1.

Quality evaluation revealed that the studies included in the meta-analysis were of an overall good quality. The median Newcastle-Ottawa Scale score was seven, with three papers scoring seven and eight each and one scoring six [Table 2]. Five and three studies made hazard ratio and confidence interval data available for OS and RFS respectively.

Meta-analysis of overall survival

In the meta-analysis of overall survival, five studies were included (Cusumano *et al* published a death HR, whilst Vesterinen *et al* offered a HR for disease specific mortality – both were deemed to be surrogate markers of OS).(17,18) Hazard ratios derived from univariate analyses were considered for

meta-analysis over their multivariate counterparts in an effort to limit the heterogeneity resulting from how hazard ratios are derived. The heterogeneity was high: $I^2 = 69\%$. This necessitated use of a random effects model. The pooled HR for Ki-67 was 2.02 (95% CI 1.16 – 3.52) with a p-value of 0.01 [Figure 2].

Meta-analysis of recurrence free survival

In the meta-analysis of recurrence free survival (RFS), three studies were available (in one recurrence HR was available whilst a second study provided a time to progression HR – both were considered to be surrogate markers of RFS). Once again, the heterogeneity was high ($l^2 = 89\%$) and therefore a random effects model was appropriate. The pooled HR was 1.42 (95% CI 1.01-2.00; p 0.04) [Figure 3].

Risk of bias

Despite the intention to assess the risk of bias using funnel-plot visual inspections, Begg's and Egger's test, this was not feasible due to the low number of studies included in the meta-analysis.

DISCUSSION

Prognostic biomarkers and tools play an important role in oncological management and decision making processes. In pulmonary NENs the dearth of prognostic biomarkers is notable and therefore oncologists often request Ki-67 indices in order to assist in therapeutic decisions despite the fact this has not been formally adopted. The primary aim of this study was to evaluate whether existing Ki-67 LI is associated with prognosis in pulmonary NENs as has been demonstrated in numerous other tumour types (e.g. GEP-NENs, urothelial carcinomas, breast cancer, lymphoma and lung cancer).

Ki-67 is most frequently evaluated immunohistochemically on paraffin sections using the MIB-1 antibody. Scoring is generally formulated by the percentage of tumour cells stained positively to the antigen (also known as the labelling index). Several methods are available to evaluate the Ki-67 labelling index (LI), including digital image analysis, eyeball estimation and manual counting. In digestive NENs, the method currently considered 'gold standard' is to evaluate the area with the most dense Ki-67 staining (i.e. histological 'hotspots') and to subsequently manually count a minimum of 500 cells, with best practice being to count 2000 cells or 2mm².(25,26) Manual counting is subject to limitations - not only can it become tedious, but it is time-consuming as counting 2000 cells can take approximately 40 minutes to complete. Utilising camera captured printed images reduces issues with inter-observer variability, although the issue of intra-tumoural heterogeneity remains as selecting

BMJ Open

which tumour area will be subjected to counting can be difficult to establish with consistency.(27) Therefore, some pathologists resort to eyeball estimations, resulting in poor reproducibility and interobserver variability relating to the pathologists experience.(28) Digital image analysis has been heralded as a means of deriving uniformity, but it is not currently widely employed as a result of a number of obstacles including technical issues (e.g. overcounting unwanted cells and underestimating negative cells) as well as its current lack of worldwide availability.

This meta-analysis provides tentative evidence demonstrating that high Ki-67 indices are associated with a 40% greater risk of recurrence amongst patients diagnosed with pulmonary NENs. This risk appears to be further exaggerated when considering overall survival where patients with a high Ki-67 have double the risk of death in comparison with patients with a lower Ki-67 LI. The strength of the association between Ki-67 LI and prognosis was only evaluated in studies that calculated hazard ratios using univariate analyses. As a result, no attempt has been made to account for confounding factors (such as stage, grade, and mitotic index).

One of the major pitfalls of including Ki-67 in the classification of pulmonary NENs has in establishing the most appropriate thresholds or cut-offs that should be utilised when grading tumours. In the main, Ki-67 has not been used as a linear biomarker within the whole pulmonary NEN cohort, instead focusing on its utility within each categorical histological subtype. Whilst categorising NENs by grade is helpful in establishing management plans, it is likely that proliferative markers (such as Ki-67 and mitotic index) are continuous rather than categorical variables. Therefore, there may not be a single or absolute optimal cut off value to categorise tumours into distinct entities and a pragmatic approach is likely to be needed. In order to facilitate clinical clarity, it would be preferable to use the same thresholds as are utilised in GEP-NETs and any future studies should attempt to clarify this further. However, it is unclear whether attempting to implement a similar grading system in pulmonary NENs as GEP NENs does a disservice to the fundamental biological diversity between the two different tumour sites.(29) Examples of this diversity include the variability of genetic alterations seen as well as the differing rates of associated syndromes and hormone expression . (30-35)

Unfortunately only two studies involving SCLC and high grade neuroendocrine carcinomas of the lung were available. It is important to clarify that Ki-67 is not likely to be useful in subtyping these tumours prognostically. A number of biomarkers have been identified which may have greater utility in these patients. Nevertheless further research into Ki-67 is required in these tumour groups with such little evidence, especially in light of the fact that in GEP-NENs there is good evidence to suggest that Ki-67 is contributory with a cut-off of 55%.(36)

BMJ Open

As with all studies, this meta-analysis is also subject to inherent limitations. None of the studies included in the meta-analyses were prospective in design; retrospective analyses are prone to error through issues with selection bias and reporting. Secondly, studies with a variety of endpoints (e.g. RFS analyses included studies where the endpoint was DFS and time to progression analyses etc.), diverse cohort sizes, differences in the dilution of the primary antibody as well as variable Ki-67 cut-offs have all been amalgamated. Whilst some degree of heterogeneity is always to be expected, it diminishes the validity of the combined data-set and subsequent results. This is reflected in the l² statistics noted across both meta-analyses.

This study also preferentially utilised univariate analyses. Whilst multivariate analyses can be significantly distorted by differing in their approach to modelling or prognostic factors, univariate analyses fail to account for confounding variables. Furthermore, given the small number of studies identified as suitable for inclusion in this meta-analysis, it is clear that future international multi-centre efforts are needed to develop studies which are prospective with large cohorts to clarify whether Ki-67 labelling index is truly a prognostic biomarker in the setting of bronchopulmonary neuroendocrine neoplasms.

CONCLUSIONS

Although it is difficult to draw definitive conclusions, this meta-analysis of over 1250 patients with pulmonary NENs indicates that a high Ki-67 LI is associated with an adverse prognosis. Whilst these findings are subject to a number of limitations, they provide a valuable insight into a rare tumour and should be considered when producing new guidelines regarding the use of Ki-67 in pulmonary NENs.

Conflict of interest statement: The authors have declared no competing interests.

Funding Statement: This research is an academic spontaneous study, which received no specific grant from any funding agency, commercial or not-for profit sectors.

SN's postgraduate studies are funded by PLANETS Cancer Charity, a not for profit organisation which had no role in developing this protocol or performing the meta-analysis.

Patient and public involvement: Patients and the public were not involved in the development of this systematic review or meta-analysis.

Data Availability Statement: All data relevant to the study are included in the article or uploaded as supplementary information.

Ethics Statement: Given that this is a systematic review of existing literature, ethical approval is not required.

Contributors: SN contributed to the study question, protocol design, screening, data collection, data analysis, dissemination of results including preparation of the manuscript. CH contributed to the screening and data collection. LT, NP, BG and EJ contributed to protocol design. LP assisted with the statistical analysis. CHO, JC and GP were responsible for the study question; all authors have been involved in the preparation of the manuscript.

Figure Legends:

Figure 1: Study Selection

Figure 2: Forest plot of studies evaluating the association between Ki-67 expression and overall survival in pulmonary neuroendocrine neoplasms.

CI = confidence interval

Figure 3: Forest plot of studies evaluating the association between Ki-67 expression and recurrence free survival in pulmonary neuroendocrine neoplasms.



REFERENCES

- 1. Travis WD Burke AP, Marx A, Nicolson AG. BE. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. *Int Agency Res Cancer.* 2015.
- 2. Asamura H, Kameya T, Matsuno Y, Noguchi M, Tada H, Ishikawa Y, et al. Neuroendocrine neoplasms of the lung: A prognostic spectrum. *J Clin Oncol.* 2006;24(1):70–6.
- Ducrocq X, Thomas P, Massard G, Barsotti P, Giudicelli R, Fuentes P, et al. Operative risk and prognostic factors of typical bronchial carcinoid tumors. *Ann Thorac Surg*. 1998;65(5):1410–4.
- Soga J, Yakuwa Y. Bronchopulmonary carcinoids: An analysis of 1,875 reported cases with special reference to a comparison between typical carcinoids and atypical varieties. *Ann Thorac Cardiovasc Surg.* 1999;5(4):211–9.
- Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. *Int J cancer*. 1983 ;31(1):13–20.
- 6. Menon SS, Guruvayoorappan C, Sakthivel KM, Rasmi RR. Ki-67 protein as a tumour proliferation marker. *Clin Chim Acta*. 2019;491:39–45.
- 7. Cuylen S, Blaukopf C, Politi AZ et al. Ki-67 acts as a biological surfactant to disperse mitotic chromosomes. *Nature*. 2016; 535(7611):308-12.
- de Azambuja E, Cardoso F, de Castro G, Colozza M, Mano MS, Durbecq V, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients. *Br J Cancer*. 2007;96(10):1504–13.
- Khor L-Y, Bae K, Paulus R, Al-Saleem T, Hammond ME, Grignon DJ, et al. MDM2 and Ki-67 Predict for Distant Metastasis and Mortality in Men Treated With Radiotherapy and Androgen Deprivation for Prostate Cancer: RTOG 92-02. *J Clin Oncol*. 2009;27(19):3177–84.
- Jann H, Roll S, Couvelard A, Hentic O, Pavel M, Müller-Nordhorn J, et al. Neuroendocrine tumors of midgut and hindgut origin: Tumor-node-metastasis classification determines clinical outcome. *Cancer*. 2011;117(15):3332–41.
- 11. Klöppel G, La Rosa S. Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms. *Virchows Arch*. 2018;472(3):341–9.
- Taylor SR, Ewings SM, Jaynes E, Tilley C, Ellis SG, Armstrong T, et al. The assessment of Ki-67 as a prognostic marker in neuroendocrine tumours: A systematic review and meta-analysis. *J Clin Pathol.* 2016;69(7):612–8.
- 13. Pelosi G, Bianchi F, Hofman P, Pattini L, Ströbel P, Calabrese F. Recent advances in the

1		
2 3 4		molecular landscape of lung neuroendocrine tumors. Expert Rev Mol Diagn. 2019;19(4):1–17.
5 6 7 8 9	14.	Klimstra D, Kloppel G, La Rosa Salas B et al. Classification of neuroendocrine neoplasms of the digestive system. In <i>WHO Classification of Tumours. Digestive System Tumours.</i> 2019 (5 th ed):16-21.
10 11 12 13 14	15.	Marchevsky AM, Hendifar A, Walts AE. The use of Ki-67 labeling index to grade pulmonary well-differentiated neuroendocrine neoplasms: current best evidence. <i>Mod Pathol</i> . 2018;31(10):1523–31.
15 16 17	16.	Naheed S, Holden C, Tanno L, Jaynes E, Cave J <i>et al</i> . The Utility Of Ki-67 As A Prognostic Biomarker In Pulmonary Neuroendocrine Tumours : <i>BMJ Open;</i> 2019 Aug 24;9(8):e031531.
18 19 20 21	17.	Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. <i>Eur J Epidemiol</i> . 2010;25(9):603–5.
22 23 24 25 26	18.	Cusumano G, Fournel L, Strano S, Damotte D, Charpentier MC, Galia A, et al. Surgical Resection for Pulmonary Carcinoid: Long-Term Results of Multicentric Study-The Importance of Pathological N Status, More Than We Thought. <i>Lung.</i> 2017; 195(6):789–98.
27 28 29 30 31	19.	Vesterinen T, Mononen S, Salmenkivi K, Mustonen H, Ilonen I, Knuuttila A, et al. Clinicopathological indicators of survival among patients with pulmonary carcinoid tumor. <i>Acta</i> <i>Oncol (Madr)</i> . 2018 57(8):1109–1116.
32 33 34	20.	Marchio C, Gatti G, Massa F, Bertero L, Filosso P, Pelosi G, et al. Distinctive pathological and clinical features of lung carcinoids with high proliferation index. <i>Virchows Arch</i> . 471(6):713–20.
35 36 37 38 39	21.	Filosso PL, Oliaro A, Ruffini E, Bora G, Lyberis P, Asioli S, et al. Outcome and prognostic factors in bronchial carcinoids: A single-center experience. <i>J Thorac Oncol</i> . 2013;8(10):1282–8.
40 41 42 43 44	22.	Clay V, Papaxoinis G, Sanderson B, Valle JW, Howell M, Lamarca A, et al. Evaluation of diagnostic and prognostic significance of Ki-67 index in pulmonary carcinoid tumours. <i>Clin Transl Oncol</i> . 2017;19(5):579–86.
45 46 47 48 49	23.	Rindi G, Klersy C, Inzani F. A three tier grading system based on Ki-67 index, mitotic count and necrosis with cut-offs specifically generated for lung neuroendocrine tumors is prognostically effective and accurate. <i>Neuroendocrinology</i> . 2014;99:251.
50 51 52 53 54 55 56	24.	de M Rego Juliana Florinda, de Medeiros RSS, Braghiroli MI, Galvao B, Neto JEB, Munhoz RR, et al. Expression of ERCC1, Bcl-2, Lin28a, and Ki-67 as biomarkers of response to first- line platinum-based chemotherapy in patients with high-grade extrapulmonary neuroendocrine carcinomas or small cell lung cancer. <i>Ecancer.</i> 2017; 11:767.
57 58 59 60	25.	Fabbri A, Cossa M, Sonzogni A, Papotti M, Righi L, Gatti G, et al. Ki-67 labeling index of neuroendocrine tumors of the lung has a high level of correspondence between biopsy samples and surgical specimens when strict counting guidelines are applied. <i>Virchows Arch</i> .

2017;470(2):153-64.

- 26. Pelosi G, Rindi G, Travis WD, Papotti M. Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice. *J Thorac Oncol.* 2014;9(3):273–84.
- 27. Reid MD, Bagci P, Ohike N, Saka B, Erbarut Seven I, Dursun N, et al. Calculation of the Ki67 index in pancreatic neuroendocrine tumors: a comparative analysis of four counting methodologies. *Mod Pathol.* 2015;28(5):686–94.


BMJ Open

- Klimstra DS, Modlin IR, Adsay NV, Chetty R, Deshpande V, Gönen M, et al. Pathology Reporting of Neuroendocrine Tumors: Application of the Delphic Consensus Process to the Development of a Minimum Pathology Data Set. *Am J Surg Pathol*. 2010;34(3):300–13.
- 29. Kasajima A, Kloppel G. Neuroendocrine neoplasms of lung, pancreas and gut: a morphologybased comparison. *Endocrine-Related Cancer.* 2020; 27(11):R417-R432.
- 30. Jiao Y, Shi C, Edil BH et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumours. *Science*. 2011; 331: 1199-1203.
- 31. Simbolo M, Barbi S, Fassan M et al. Gene expression profiling of lung atypical carcinoids and large cell neuroendocrine carcinomas identifies three transcrimptomic subtypes with specific genomic alterations. *J Thor Onc.* 2019; 14: 1651-1661.
- 32. Swarts DR, Scarpa A, Corbo V et al. MEN1 gene mutation and reduced expression are associated with poor prognosis in pulmonary carcinoids. *J Clinical Endocrinology and Metabolism* 2014; 99: E374-E378.
- Alcala N, Leblay N, Gabriel AAG et al. Integrative and comparitive genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids. *Nature Communications*. 2019; 10: 3407.
- Gustaffson BI, Kidd M, Chan A et al. Bronchopulmonary neuroendocrine tumors. *Cancer.* 2008; 113:5-21.
- Pape UF, Jann H, Muller-Nordhorn J et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumours. *Cancer.* 2008; 113:256-265.
- Sorbye H, Welin S, Langer SW et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. *Ann Oncol.* 2013; 24(1):152-160.

Author (Year)	Trial Design (study centres)	Number of Subjects	Histological subtypes	Age Range	Gender M:F	s <u>₿₩</u> J Open	Antibody	Methodology for calculating Ki-67	Median length of follow-up (months)	6/bm∰7 cut-off tඤsholds දෙ 2020-C	Outcome measure	Hazard Ratige (95% CI) from univariate analyses
Cusumano et al (2017)	Retrospective multicentre study (France, Italy)	195	TC (159); AC (36)	52.94 (TC); 60.16 (AC) [mean values]	89:106	I = 163; II = 16; III = 16; IV = 0	NR	NR	75 (mean)	04 <u>4</u> 961 on 3	OS (Death HR) DFS	1.07 (0.97- 1.17) 0.97 (1.01- 1.2)
Rego et al (2017)	Retrospective, multicentre study (Brazil)	82	SCLC (82)	35-81 (mean 59)	48:34	I = 0; II = 0; III = 6; IV = 76	MIB-1 (1:1000)	Hotspot method; otherwise not specified	10.3	Margh 2022. D	OS	1.15 (0.70- 1.89)
Marchio et al (2017)	Retrospective multicentre study (Italy)	239	TC (171); AC (68)	NR	100:139	NR	NR	Manual counting of >1000 cells	NR	ownloaded fron	OS TTP	4.31 (1.624- 11.45) 3.994 (1.58- 10)
Filosso et al (2013)	Retrospective, single centre study (Italy)	126 [NB 110 included in Ki-67 analysis]	TC (83); AC (43). [In Ki- 67 analysis TC (79); AC (31)]	15-82 (mean 60)	52:74	I = 90; II = 18; III = 16; IV = 2; X = 1	anti–Ki-67 antibody (DAKO) not further specified	NR	60	흋2020-044961 on 3 Marsh 2022. Downloaded from http://bmjopen.b	OS	2.08 (1.02- 4.27)
Rindi et al (2014)	Retrospective, multicentre study (Italy)	399	TC (113); AC (84); LCNEC (94); SCLC (108)	63.26 (median)	245:154	I = 183; II = 90; III = 76; IV = 17; X = 33	MIB-1 antibody	Computer assisted manual count method 500- 2000 cells	70.72	<4 vs 4-20	OS	1.26 (0.84- 1.89)
Clay et al (2017)	Retrospective, single centre study (UK)	94 [NB survival analysis performed on 84]	TC (75); AC (19) [NB survival analysis performed 67 TC, 17 AC patients]	21-83 (median 60.5)	39:55	NR	MIB-1 antibody (1:50)	Manual count method 500- 2000 cells in hot spot	35	com/ on Apr <mark>⊭</mark> 19, 2024 by gues	RFS	1.47 (1.25- 1.74)
Vesterinen et al (2018)	Retrospective, single centre study (Finland)	133 (129 included in Ki-67 analysis)	TC (100); AC (33)		47:86	NR	MIB-1 antibody (1:100)	Manual and automated counting of 2000 cells	9.6	2 ² Protected	Disease specific mortality	10.51 (2.12- 52.13)
1: Main Ch	aracteristics	of all studie	es included i	n the meta-a	analysis.					by co	•	
iale, F=tem	ale, NR = not	recorded, (DS = overall s	survival, RFS			al, DFS = dise	ease free surv	/ival, TTP =	timeto progr	ession.	
						16				.t.		
			For	peer review c	only - http://b	mjopen.bmj.o	com/site/abo	ut/guidelines	xhtml			

Page 19 of 24					BMJ Open			5/bmjopen-202 Adequacy of	
1 2 Author (Year) 3 4 5 6 7	Representativenes s of cohort (1 point)	Adequate definition of cases (1 point)	Assessment of exposure (1 point)	Outcome of interest not present at start of study (1 point)	Comparibility on the basis of the design or analysis	Assessment of Outcome (death or recurrence) (1 point)	Adequacy of median follow- up for outcome (>2 years)	fellow-up of cases (<20% or -reported)	Total Quality Score
8					(2 points)	,	(1 point)	arch	
9 10 11 ⁽²⁰¹⁷⁾ 12	\checkmark	Δ	À	-	A A	\mathbf{A}	Δ	March 2022. Dov	8
13 _{Rego et al} 14 ₍₂₀₁₇₎ 15 16	Δ	${\mathbf{A}}$	*	5	${\swarrow}$	Δ	-	vnloaded fr	6
1 <i>7</i> Marchio et al 1& ₂₀₁₇₎ 19	\$	${\mathbf{A}}$	*	·99	**	Δ	-	om http://br	7
20 21 ^{Filosso et al} 2 <u>2</u> 2013) 23	\$	${\mathbf{A}}$	${\swarrow}$	-	**	\$	${\mathbf{A}}$	njopen.bmj.	8
24 25 26 ²⁰¹⁴⁾ 27	分	\$	$\overset{\mathbf{A}}{\sim}$	-	**	\$	\$	com/ on Ap	8
28Clay et al (2017) 29 30 31	\$	\$	$\overset{\mathbf{A}}{\sim}$	-	$\overset{\Lambda}{\sim}$	*	\$	ril 19, 2024	7
32/esterinen et al 33 ₍₂₀₁₈₎ 34 35 36	\$	\$	*	-	☆☆	Δ		Ą ∕∕ by guest. Protec	7
37 38 39 40 41 42				1	7			Image: Arrow of the system Image: Arrow of the system <td< td=""><td></td></td<>	
43 44 45			For peer revie	ew only - http://b	mjopen.bmj.com,	/site/about/guide	lines.xhtml		

Table 2: Quality assessment	BMJ Open t of included studies utilising the (modified) Newcastle-Ottawa	6/bmjopen-2020-041961 on 3 March 2022. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.
1 Scale.		n-20
2		20-0
3)419
4		961
5 6		9 C
7	Con Deer review only	3 Ma
8		arch
9		202
10 11		22. [
12		Dow
13	O _b	nlo
14		ade
15 16		d fro
17		Ĭ
18		:dit
19		//bn
20 21		qojc
21		en.k
23		<u>ă</u>
24		Som
25 26		v on
20 27		Ap
28		⊒: 1
29		9,2
30		024
31 32		by
33		gue
34		st. F
35		rot
36 37		ecte
38		ğ
39		۷ C
40		уруг
41	18	ight
42 43		•
44	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	
45		
46		



1											
2											
3											
4											
5											
6											
7											
8											
9											
10											
11											
12											
13											
14											
15											
16											
17											
18											
19											
20											
21											
22											
23											
24						Hazard Ratio			azard Ratio		
25	Study or Subgroup log	g[Hazard Ratio] SE	Total 1	Fotal	Weight		ar		azaro Ratio andom, 95%	CI	
26 -	Filosso 2013	0.7324 0.3636	0	0	21.2%	2.08 [1.02, 4.24] 201		10,10			
27	Rindi 2014	0.2311 0.2069	0	0	27.8%				- -		
28	Rego 2017	0.1398 0.2533	0	0	25.9%	1.15 [0.70, 1.89] 201					
29	Marchio 2017	1.4609 0.498	0	0	16.3%	4.31 [1.62, 11.44] 201					
30	Vesterinen 2018	2.3523 0.8168	0	0	8.8%	10.51 [2.12, 52.10] 201	8		<u> </u>	•	_
31	T (1/05% O))		•	•	400.00/	0.00.14.40.0.501					
32	Total (95% CI)	01.12 40.75 If 4 (D. 0	0		100.0%	2.02 [1.16, 3.52]			•		
32 33	Heterogeneity: Tau ² = 0.25;					2.02 [1.16, 3.52]	⊢ 0.01	0.1	1	10	100
32 33 34						2.02 [1.16, 3.52]	L 0.01	0.1	1		100
32 33 34 35	Heterogeneity: Tau ² = 0.25;					2.02 [1.16, 3.52]	L 0.01	0.1	1	10	100
32 33 34 35 36	Heterogeneity: Tau ² = 0.25;					2.02 [1.16, 3.52]	⊢ 0.01	0.1	1	10	100
32 33 34 35 36 37	Heterogeneity: Tau ² = 0.25; Test for overall effect: Z = 2	2.47 (P = 0.01)	0.01); I²	= 69%	, D						100
32 33 34 35 36 37 38	Heterogeneity: Tau ² = 0.25; Test for overall effect: Z = 2 Figure 2: Forest p	2.47 (P = 0.01) lot of studies evalua	0.01); I ²	= 69%	, D	tion between Ki-67	expressi	on and ov	1 Verall surv		100
32 33 34 35 36 37 38 39	Heterogeneity: Tau ² = 0.25; Test for overall effect: Z = 2 Figure 2: Forest p	2.47 (P = 0.01)	0.01); I ²	= 69%	, D	tion between Ki-67	expressi	on and ov	1 verall surv		100
32 33 34 35 36 37 38 39 40	Heterogeneity: Tau ² = 0.25; Test for overall effect: Z = 2 Figure 2: Forest pi pulmonary neuroe	2.47 (P = 0.01) lot of studies evalua endocrine neoplasm	0.01); I ²	= 69%	, D	tion between Ki-67	expressi	on and ov	1 verall surv		100
32 33 34 35 36 37 38 39 40 41	Heterogeneity: Tau ² = 0.25; Test for overall effect: Z = 2 Figure 2: Forest p	2.47 (P = 0.01) lot of studies evalua endocrine neoplasm	0.01); I ²	= 69%	, D	tion between Ki-67	expressi	on and ov	1 /erall surv		100
32 33 34 35 36 37 38 39 40 41 42	Heterogeneity: Tau ² = 0.25; Test for overall effect: Z = 2 Figure 2: Forest pi pulmonary neuroe	2.47 (P = 0.01) lot of studies evalua endocrine neoplasm	0.01); I ²	= 69%	, D	tion between Ki-67		on and ov	1 /erall surv		100
32 33 34 35 36 37 38 39 40 41 42 43	Heterogeneity: Tau ² = 0.25; Test for overall effect: Z = 2 Figure 2: Forest pi pulmonary neuroe	2.47 (P = 0.01) lot of studies evalua endocrine neoplasm	0.01); I ²	= 69%	, D	tion between Ki-67	expressi	on and ov	verall surv		100
32 33 34 35 36 37 38 39 40 41 42 43 44	Heterogeneity: Tau ² = 0.25; Test for overall effect: Z = 2 Figure 2: Forest pi pulmonary neuroe	2.47 (P = 0.01) lot of studies evalua endocrine neoplasm	0.01); I ²	= 69%	, D	tion between Ki-67	expressi	on and ov	1 verall surv		100
32 33 34 35 36 37 38 39 40 41 42 43 44 45	Heterogeneity: Tau ² = 0.25; Test for overall effect: Z = 2 Figure 2: Forest pi pulmonary neuroe	2.47 (P = 0.01) lot of studies evalua endocrine neoplasm	0.01); I ²	= 69%	, D	tion between Ki-67	expressi	on and ov	1 verall surv		100
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46	Heterogeneity: Tau ² = 0.25; Test for overall effect: Z = 2 Figure 2: Forest pi pulmonary neuroe	2.47 (P = 0.01) lot of studies evalua endocrine neoplasm	0.01); I ²	= 69%	, D	tion between Ki-67	expressi	on and ov	1 /erall surv		100
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47	Heterogeneity: Tau ² = 0.25; Test for overall effect: Z = 2 Figure 2: Forest pi pulmonary neuroe	2.47 (P = 0.01) lot of studies evalua endocrine neoplasm	0.01); I ²	= 69%	, D	tion between Ki-67	expressi	on and ov	1 verall surv		100
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48	Heterogeneity: Tau ² = 0.25; Test for overall effect: Z = 2 Figure 2: Forest pi pulmonary neuroe	2.47 (P = 0.01) lot of studies evalua endocrine neoplasm	0.01); I ²	= 69%	, D	tion between Ki-67	expressi	on and ov	1		100
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49	Heterogeneity: Tau ² = 0.25; Test for overall effect: Z = 2 Figure 2: Forest pi pulmonary neuroe	2.47 (P = 0.01) lot of studies evalua endocrine neoplasm	0.01); I ²	= 69%	, D	tion between Ki-67	expressi	on and ov	1 verall surv		100
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50	Heterogeneity: Tau ² = 0.25; Test for overall effect: Z = 2 Figure 2: Forest pi pulmonary neuroe	2.47 (P = 0.01) lot of studies evalua endocrine neoplasm	0.01); I ²	= 69%	, D	tion between Ki-67	expressi	on and ov	1 verall surv		100
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51	Heterogeneity: Tau ² = 0.25; Test for overall effect: Z = 2 Figure 2: Forest pi pulmonary neuroe	2.47 (P = 0.01) lot of studies evalua endocrine neoplasm	0.01); I ²	= 69%	, D	tion between Ki-67	expressi	on and ov	/verall surv		100
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52	Heterogeneity: Tau ² = 0.25; Test for overall effect: Z = 2 Figure 2: Forest pi pulmonary neuroe	2.47 (P = 0.01) lot of studies evalua endocrine neoplasm	0.01); I ²	= 69%	, D	tion between Ki-67	expressi	on and ov	1 verall surv		100
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53	Heterogeneity: Tau ² = 0.25; Test for overall effect: Z = 2 Figure 2: Forest pi pulmonary neuroe	2.47 (P = 0.01) lot of studies evalua endocrine neoplasm	0.01); I ²	= 69%	, D	tion between Ki-67	expressi	on and ov	1 verall surv		100
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54	Heterogeneity: Tau ² = 0.25; Test for overall effect: Z = 2 Figure 2: Forest pi pulmonary neuroe	2.47 (P = 0.01) lot of studies evalua endocrine neoplasm	0.01); I ²	= 69%	, D	tion between Ki-67	expressi	on and ov	1 verall surv		100
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55	Heterogeneity: Tau ² = 0.25; Test for overall effect: Z = 2 Figure 2: Forest pi pulmonary neuroe	2.47 (P = 0.01) lot of studies evalua endocrine neoplasm	0.01); I ²	= 69%	, D	tion between Ki-67	expressi	on and ov	1 verall surv		100
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56	Heterogeneity: Tau ² = 0.25; Test for overall effect: Z = 2 Figure 2: Forest pi pulmonary neuroe	2.47 (P = 0.01) lot of studies evalua endocrine neoplasm	0.01); I ²	= 69%	, D	tion between Ki-67	expressi	on and ov	1 /erall surv		100
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57	Heterogeneity: Tau ² = 0.25; Test for overall effect: Z = 2 Figure 2: Forest pi pulmonary neuroe	2.47 (P = 0.01) lot of studies evalua endocrine neoplasm	0.01); I ²	= 69%	, D	tion between Ki-67	expressi	on and ov	/erall surv		100
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58	Heterogeneity: Tau ² = 0.25; Test for overall effect: Z = 2 Figure 2: Forest pi pulmonary neuroe	2.47 (P = 0.01) lot of studies evalua endocrine neoplasm	0.01); I ²	= 69%	, D	tion between Ki-67	expressi	on and ov	/erall surv		100
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57	Heterogeneity: Tau ² = 0.25; Test for overall effect: Z = 2 Figure 2: Forest pi pulmonary neuroe	2.47 (P = 0.01) lot of studies evalua endocrine neoplasm nterval	0.01); I ²	= 69%	ssocia	tion between Ki-67	expressi	on and ov	verall surv		100

						Hazard Ratio			lazard Ratio		
Study or Subgroup	log[Hazard Ratio]	SE	Total	Total	Weight	IV, Random, 95% Cl		IV, R	andom, 95%	CI	
Clay 2017	0.3853	0.0827	0	0	43.0%	1.4701 [1.2501, 1.7287]			-		
Cusumano 2017	0.0862	0.0389	0	0	46.5%	1.0900 [1.0100, 1.1764]			•		
Marchio 2017	1.3848	0.4732	0	0	10.5%	3.9940 [1.5799, 10.0972]				•	-
Total (95% CI)			0	0	100.0%	1.4202 [1.0110, 1.9951]			•		
Heterogeneity: Tau ^a = 0.06; Chi ^a = 17.59, df = 2 (P = 0.0002); i ^a = 89% Test for overall effect: Z = 2.02 (P = 0.04)								0.2	1	5	

Figure 3: Forest plot of studies evaluating the association between Ki-67 expression and recurrence free survival in pulmonary neuroendocrine neoplasms.

CI = confidence interval.

EXAMPLE OF FULL SEARCH STRATEGY

The systematic review will employ the following search terms for Medline OVID, and EMBASE:

Ki-67 antigen/ OR (Ki67 or Ki-67 or mib-1 or mib1).mp.

AND

neuroendocrine tumors/ or carcinoid tumor/ or carcinoma, neuroendocrine/ OR small cell lung carcinoma/ OR ((tumo?r* or neoplas* or carcinoma or cancer* or malignan*) adj3 (neuroendocrine or carcinoid or small cell)).mp. to per terien ont

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml



PRISMA 2009 Checklist

Pa	age 25 of 24		BMJ Open 13 66	
1 2	PRISMA 20	Checklist ^{mjopen-20}		
3 4 5	Section/topic	#	Checklist item	Reported on page #
6 7	TITLE			
8	Title	1	Identify the report as a systematic review, meta-analysis, or both. $\overset{\omega}{\underline{s}}$	1
9 1(ABSTRACT		arch	
11 12 13	Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data source study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
15	INTRODUCTION			
16	Rationale	3	Describe the rationale for the review in the context of what is already known.	3-4
18	Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, ingerventions, comparisons, outcomes, and study design (PICOS).	4
20	METHODS			
2 22 23	Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and if available, provide registration information including registration number.	4
24 25	5,	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5
26 27	Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
29 30	Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	5
31	Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	5
34 35	Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	5
36		11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	5
39 39 4(atudiaa	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	5-6
4	Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	5-6
44 43 44	-	14	Describe the methods of handling data and combining results of studies, if done, including near assures of consistency (e.g., l ²) for each meta-analysis.	5-6
45 46 47	5		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml Page 1 of 2	J



PRISMA 2009 Checklist

		BMJ Open 30	Page 26 of 24
PRISMA 20	009	Checklist Phere 202	
Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	5-6
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	5-6
RESULTS		022	
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	6
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	6-7
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	7
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summare data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	6-7
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of sonsistency.	7
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	7
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	7
DISCUSSION	<u> </u>		
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	7-8
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	7-8
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implication before future research.	9
	<u> </u>	e St	
, Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data; role of funders for the systematic review.	6
	_ _		
From: Moher D, Liberati A, Tetzlaff doi:10.1371/journal.pmed1000097	J, Altm	an DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The RISMA Statement. PLoS Med	6(6): e1000097.
<u>)</u>		For more information, visit: <u>www.prisma-statement.org</u> .	
3		Page 2 of 2	
4 5 6		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	